{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can losartan reduce brain atrophy in Alzheimer's disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"INTERPRETATION: 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is CHARMS with respect to medical review of predictive modeling?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.RESULTS: From the 29\"}, {\"id\": 29, \"text\": \"However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements).\"}, {\"id\": 22, \"text\": \"The authors did not put any restrictions on the models included in their study regarding the model setting, prediction horizon or outcomes.Data extraction and synthesis Checklists of critical appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS) and prediction model risk of bias assessment tool (PROBAST) were used to guide developing of a standardised data extraction form.\"}, {\"id\": 2, \"text\": \"We critically appraised these models by means of criteria derived from the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies) and PROBAST (Prediction model Risk Of Bias ASsessment Tool).\"}, {\"id\": 18, \"text\": \"ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment too\"}, {\"id\": 10, \"text\": \"Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.\"}, {\"id\": 6, \"text\": \"ion making. Systematic reviews of prognostic model studies can help identify prognostic models that need to further be validated or are ready to be implemented in healthcare.OBJECTIVES: To provide a step-by-step guidance on how to conduct and read a systematic review of prognostic model studies and to provide an overview of methodology and guidance available for every step of the review progress.SOURCES: Published, peer-reviewed guidance articles.CONTENT: We describe the following steps for conducting a systematic review of prognosis studies: 1) Developing the review question using the Population, Index model, Comparator model, Outcome(s), Timing, Setting format, 2) Searching and selection of articles, 3) Data extraction using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) checklist, 4) Quality and risk of bias assessment using the Prediction model Risk Of Bias ASsessment (PROBAST) tool, 5) Analysing data and undertaking quantitative meta-analysis, and 6) Presenting summary of findings, inte\"}, {\"id\": 4, \"text\": \"ist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist. In total 89,959 citations wer\"}, {\"id\": 19, \"text\": \"Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).\"}, {\"id\": 1, \"text\": \"Data collection was guided by the checklist for critical appraisal and data extraction for systematic reviews (CHARMS) and applicability and methodological quality assessment by the prediction model risk of bias assessment tool (PROBAST).\"}, {\"id\": 15, \"text\": \"The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodolog\"}, {\"id\": 20, \"text\": \"the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information\"}, {\"id\": 24, \"text\": \"The CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) checklist was used for data extraction and quality assessment.\"}, {\"id\": 28, \"text\": \"t for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME M\"}, {\"id\": 26, \"text\": \"nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation and discussion.RESULTS: We found tw\"}, {\"id\": 25, \"text\": \"acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of \"}, {\"id\": 17, \"text\": \"nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of da\"}, {\"id\": 5, \"text\": \"We will extract data based on the Checklist for\\u00c2\\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS), \"}, {\"id\": 0, \"text\": \"CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).\"}, {\"id\": 11, \"text\": \"te, or status of the publication. To carry out the systematic review, the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) guidel\"}, {\"id\": 12, \"text\": \"Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)\"}, {\"id\": 14, \"text\": \"inclusion criteria). We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data\"}, {\"id\": 16, \"text\": \"methods in oncology. We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement, Prediction model Risk Of Bias ASsessment Tool (PROBAST) and CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) to assess the methodological conduct of i\"}, {\"id\": 13, \"text\": \"The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews.\"}, {\"id\": 9, \"text\": \"ist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsess\"}, {\"id\": 8, \"text\": \"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist.\"}, {\"id\": 23, \"text\": \"t for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEASURES: P\"}, {\"id\": 21, \"text\": \"acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the ri\"}, {\"id\": 7, \"text\": \"the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc). We determin\"}, {\"id\": 27, \"text\": \"tudies with model updating. Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEA\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 5, 19, 12, 13, 29, 27, 1, 10, 16, 14, 8, 24, 6, 11, 22, 2, 9, 28, 20, 15, 4, 21, 18, 17, 23, 7, 25, 3, 26]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which splicing factors have been associated with alternative splicing in PLN R14del hearts?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart.\"}, {\"id\": 0, \"text\": \"Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the most common mutation types in Duchenne muscular Dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 8, \"text\": \"l spectrum. This information is extremely beneficial for basic scientific research, genetic diagnosis, trial planning, clinical care, and gene therapy.METHODS: We collected data from 1400 patients (1042 patients with confirmed unrelated Duchenne muscular dystrophy [DMD] or Becker muscular dystrophy [BMD]) registered in the Chinese Genetic Disease Registry from March 2012 to August 2017 and analyzed the genetic mutational characteristics of these patients.RESULTS: Large deletions were the most frequent type of mutation (72.2%), followed by nonsense mutations (11.9%), exon duplications (8.8%), small deletions (3.0%), splice-site mutations (2.1%), small insertions (1.3%), missense mutations (0.6%), and a combination mutation of a dele\"}, {\"id\": 1, \"text\": \"Of these, 406 (70.5%) were exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%). Small mutations were identified in 105 cases (18.2%), most being nonsense/frameshift types (75.2%). Mutations in splice sites, however, were relatively frequent (20%). \"}, {\"id\": 2, \"text\": \"Deletions were the most common mutation type (256, 79%), followed by point mutations (45, 13.9%) and duplications (23, 7.1%).\"}, {\"id\": 4, \"text\": \" 64% deletions, 18% duplications and 18% point mutations. \"}, {\"id\": 6, \"text\": \"In all the patients with gene deletion and duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD, 9.4% (44/467).\"}, {\"id\": 0, \"text\": \"While in earlier studies equal mutation rates in males and females had been reported, a breakdown by mutation types can better explain the sex ratio of mutations: Point mutations and duplications arise preferentially during spermatogenesis whereas deletions mostly arise in oogenesis.\"}, {\"id\": 7, \"text\": \"The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations). \"}, {\"id\": 5, \"text\": \"gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6% (76/720)\"}, {\"id\": 9, \"text\": \"The rate of deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion patients; meanwhile, the rate of gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones.\"}, {\"id\": 3, \"text\": \"The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 1, 5, 9, 6, 7, 3, 0, 8, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the target of Litifilimab?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.\"}, {\"id\": 0, \"text\": \" The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2, in patients with SLE have not been extensively studied.\"}, {\"id\": 3, \"text\": \"Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.\"}, {\"id\": 1, \"text\": \"Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 2, 1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is AUROC in context of predictive modeling?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 23, \"text\": \"sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) sc\"}, {\"id\": 2, \"text\": \"ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) an\"}, {\"id\": 29, \"text\": \"The area under the receiver operating characteristic (ROC) curve (AUC) is commonly used for assessing the discriminative ability of prediction models even though the measure is criticized for being clinically irrelevant and lacking an intuitive interpretation. Every tutorial explains how the coordinates of the ROC curve are obtained from the risk distributions of diseased and non-diseased individuals, but it has not become common sense that therewith the ROC plot is just another way of presenting these risk distributions. We show how the ROC curve is an alternative way to present risk distributions of diseased and non-diseased individuals and how the shape of the ROC curve informs about the overlap of the risk distributions.\"}, {\"id\": 37, \"text\": \"models of the EGFR mutation status (Model 1: area under the receiver operating characteristic curve [AUROC]\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.910, 95% CI 0.861-0.945; Model 2: AUROC\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.859, 95% CI 0.803-0.904; Model 3: AUROC\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.711, 95% CI 0.643-0.773). A testing set (n\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u203050) and temporal validation data set (n\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u203070\"}, {\"id\": 5, \"text\": \"cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was appl\"}, {\"id\": 32, \"text\": \" accuracy, precision, recall, F1 score, and Area under the\\u00c2\\u00a0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% and 61.5\"}, {\"id\": 12, \"text\": \"of outcome (AC), sensitivity (SN), specificity (SP), and area under receiver-operating curve (AUROC) were compared between 3 models: KCC (INR, creatinine, coma grade, pH), CART analysis using only KCC variables (KCC-CART) and a CART model using new variables (NEW-CART).RESULTS: Traditional KC\"}, {\"id\": 31, \"text\": \"s). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.RESUL\"}, {\"id\": 35, \"text\": \"The two approaches were explored and validated within the context of mRNA expression level prediction and have the area under the ROC curve (auROC) values ranging from 0.75 to 0.94.\"}, {\"id\": 36, \"text\": \"nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to \"}, {\"id\": 25, \"text\": \"Our models predict GDM with high accuracy even at pregnancy initiation (area under the receiver operating curve (auROC)\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.85), substantially outperforming a baseline risk score (auROC\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.68).\"}, {\"id\": 28, \"text\": \"Area under a receiver-operating-characteristic (AUROC) curve is widely used in medicine to summarize the ability of a continuous predictive marker to predict a binary outcome.\"}, {\"id\": 17, \"text\": \"s). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determi\"}, {\"id\": 34, \"text\": \" learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC). The conventional scoring models had various p\"}, {\"id\": 10, \"text\": \"Using a standard multivariate approach to combine predictors, the PPIN model achieved an AUROC (area under the receiver operating characteristic curve) of 0.81 with a sensitivity of 48% given a specificity of 90%.\"}, {\"id\": 19, \"text\": \"s), positive predictive values (PPVs), and area under the receiver operating characteristic curve (AUROC), of machine learning models when predicting \"}, {\"id\": 20, \"text\": \"Area under the receiver operating characteristics (AUROC) curve is often used to evaluate risk models.\"}, {\"id\": 22, \"text\": \"ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks. For recurrent neural netw\"}, {\"id\": 16, \"text\": \"rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive per\"}, {\"id\": 27, \"text\": \"-day mortality, respectively. When using only baseline variables to predict mortality, all algorithms except SVM (area under the receiver operator characteristic curve [AUROC], 0.83 [95% confidence interval {CI}, 0.69-0.97]) had AUROC >0.9: GBM (AUROC, 0.96 [0.94-1.0]), RF (AUROC, 0.96 [0.92-1.0]), CNN (AUROC, 0.96 [0.92-0.99]), and logistic regress\"}, {\"id\": 7, \"text\": \"The model performance was evaluated using the area under the receiver operating characteristic curve (AUROC)\"}, {\"id\": 8, \"text\": \" matrix, accuracy, precision, recall, F1 score, and Area under the\\u00c2\\u00a0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% \"}, {\"id\": 6, \"text\": \"ement (oral or IV) was 41.1%. Independent predictors using history alone were female sex, decreasing age, surgical history, and non-Caucasian ethnicity (model area under the receiver operating characteristic curve [AUROC], 0.59 [95% confiden\"}, {\"id\": 21, \"text\": \"ys). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from dat\"}, {\"id\": 0, \"text\": \"rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive\"}, {\"id\": 30, \"text\": \"sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) scores reported were included in the analysis.\"}, {\"id\": 24, \"text\": \"agnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC). Stratification analysis by age and MP-IgM tite\"}, {\"id\": 11, \"text\": \".4%) and validation (47.4%) cohorts. The FibroGENE-DT yielded the area under the receiver operating characteristic curve (AUROCs) of 0.87, 0.85 and 0.804 for the prediction of fast fibrosis progression, cirrhosis and significant fibrosis risk, respectively, with compara\"}, {\"id\": 9, \"text\": \" prediction of pancreatic cancer. Two popular models were evaluated: logistic regression and a recurrent neural network.RESULTS: For logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81\"}, {\"id\": 13, \"text\": \"ance of prediction, accuracy of discrimination (area under the receiver operating characteristic curve [AUROC]), calibration, and validity of the two predictive models were investigated. The co\"}, {\"id\": 38, \"text\": \"cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readm\"}, {\"id\": 15, \"text\": \" reduction of at least I\\u00c2\\u00b0 MR. One-year mortality was 28.2%.In Kaplan-Meier analysis, one- year mortality was significantly higher in RVD-pts (34.8% vs 2.8%, p\\u00c2\\u00a0=\\u00c2\\u00a00.009).Area under the Receiver Operating Characteristic (AUROC) for SHFM and MAGGIC were comparable for both scores\"}, {\"id\": 18, \"text\": \". The area under the receiver operator characteristics curve (AUROC)\"}, {\"id\": 4, \"text\": \"The c statistic, or area under the receiver operating characteristic (ROC) curve, achieved popularity in diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant to discriminating diseased versus nondiseased patients.\"}, {\"id\": 3, \"text\": \"area under receiver operator curve [AUROC] \"}, {\"id\": 14, \"text\": \"cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90). These models outperformed traditional, c\"}, {\"id\": 33, \"text\": \"nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.RE\"}, {\"id\": 1, \"text\": \"We assessed model performance using two metrics, the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC), to illustrate the differences in information they convey in the setting of class imbalance.\"}, {\"id\": 39, \"text\": \"stic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performa\"}, {\"id\": 26, \"text\": \"cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included. In multiple linear regression analysis of PD patients\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [18, 3, 7, 25, 9, 20, 39, 28, 4, 27, 1, 35, 11, 6, 15, 10, 5, 2, 31, 21, 24, 34, 30, 33, 38, 0, 22, 17, 23, 36, 16, 26, 12, 37, 14, 8, 32, 19, 13, 29]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is PRP-40 regulation of microexons a conserved phenomenon?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is casimersen effective for the treatment of Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Casimersen received its first approval on 25\\u00c2\\u00a0February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\u00c2\\u00a045 skipping. \"}, {\"id\": 1, \"text\": \"he approval, granted under the US FDA Accelerated Approval Program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which are the targets of Tirzepatide?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.\"}, {\"id\": 1, \"text\": \"he efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known.\"}, {\"id\": 0, \"text\": \"The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. \"}, {\"id\": 3, \"text\": \"Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 1, 2, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is medical hydrology the same as Spa therapy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"hydrotherapy,\\\" \\\"balneotherapy,\\\" \\\"spa therapy,\\\" \\\"spa treatment,\\\" \\\"creno-balneotherapy,\\\" \\\"water treatments,\\\" and \\\"aqua therapy,\\\" o\"}, {\"id\": 3, \"text\": \"Spa therapy is an integral part of the treatment of burn scars. The objective of this systematic review is to provide an overview of the spa therapy used in the treatment of burn scars and analyze its effects reported in clinical studies. We used the PRISMA checklist and queried 8 scientific databases from August 2019 to July 2020 for articles referenced with the specific key words: (burn) AND ((spa) OR (crenotherap*) OR (sulfur bath) OR (balneo*) OR (hydrotherap*) OR (mineral water) OR (thermal water) OR (spring water) OR (health resort medicine))\"}, {\"id\": 0, \"text\": \"Soon after qualification, Fortescue Fox (1858-1940) began practice in a Scottish spa where he acquired a lifelong interest in chronic disorders, especially arthritis. He worked to improve the status of spa medicine, recasting it as medical hydrology\"}, {\"id\": 2, \"text\": \"He worked to improve the status of spa medicine, recasting it as medical hydrology.\"}, {\"id\": 1, \"text\": \" He worked to improve the status of spa medicine, recasting it as medical hydrology.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 3, 0, 2, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'How does CYP1A2 relate to coffee consumption and apetite?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"High coffee consumption was more prevalent in rapid compared to slow metabolizers (P\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.008 after adjustment for age, sex, and BMI) and was associated with lower appetite perception and lower BMI only in rapid metabolizers (P for interaction of rs762551 genotype*coffee consumption\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.002 and 0.048, respectively). This differential association of rs762551 genotype and coffee consumption with BMI was more evident in individuals at higher genetic risk of obesity (mean adjusted difference in BMI\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u2030-5.82\\u00e2\\u20ac\\u2030kg/m2 for rapid versus slow/intermediate metabolizers who consumed more than 14 cups of coffee per week).\"}, {\"id\": 1, \"text\": \"CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.\"}, {\"id\": 2, \"text\": \"CYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin. This association is more evident in subjects with high genetic predisposition to obesity. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \" In this retrospective matched control study, eteplirsen treatment resulted in attenuation of ambulatory decline over a 4-year observation period, supporting long-term benefit in patients with DMD.\"}, {\"id\": 0, \"text\": \"Eteplirsen-treated patients experienced a statistically significant longer median time to LOA by 2.09 years (5.09 vs. 3.00 years, p\\u00e2\\u20ac\\u0160<\\u00e2\\u20ac\\u01600.01) and significantly attenuated rates of pulmonary decline vs. natural history patients (FVC%p change: -3.3 vs. -6.0 percentage points annually, p\\u00e2\\u20ac\\u0160<\\u00e2\\u20ac\\u01600.0001).\"}, {\"id\": 3, \"text\": \"At Years 3 and 4, eteplirsen-treated patients demonstrated markedly greater mean 6MWT than controls (difference in change from baseline of 132 m [95%CI (29, 235), p\\u00e2\\u20ac\\u0160=\\u00e2\\u20ac\\u01600.015] at Year 3 and 159\\u00e2\\u20ac\\u0160m [95%CI (66, 253), p\\u00e2\\u20ac\\u0160=\\u00e2\\u20ac\\u01600.002] at Year 4)\"}, {\"id\": 1, \"text\": \"At Year 4, a significantly greater proportion of eteplirsen-treated patients were still ambulant versus controls (10/12 vs 3/11; p\\u00e2\\u20ac\\u0160=\\u00e2\\u20ac\\u01600.020)\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 3, 1, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the use of darolutamide?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"BACKGROUND: For nonmetastatic castration-resistant prostate cancer (nmCRPC), 3 drugs under patent protection-apalutamide, enzalutamide, and darolutamide-were approved based on randomized, placebo-controlled trials; 1 drug with generic availability, abiraterone acetate, showed efficacy in a single-arm trial and is commonly prescribed.\"}, {\"id\": 2, \"text\": \"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.\"}, {\"id\": 3, \"text\": \"CONCLUSIONS: For nmCRPC, darolutamide offered optimal efficacy and safety among approved drugs, and abiraterone acetate may offer comparable metastasis-free survival benefit with cost savings from generic availability. \"}, {\"id\": 4, \"text\": \"Darolutamide is an approved treatment for a different type of prostate cancer called non-metastatic, castration-resistant prostate cancer (also called nmCRPC).\"}, {\"id\": 0, \"text\": \"CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1, 3, 2, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the main clinical features of small-fiber neuropathy (SFN)?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 8, \"text\": \"Small fiber neuropathies (SFN) comprise a clinical syndrome typically associated with acral burning pain, where the pathophysiological processes affect the thinly myelinated A-delta and the unmyelinated C nerve fibers.\"}, {\"id\": 3, \"text\": \"Up to 50% of small fiber neuropathy (SFN) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR-3) have been implicated in half of these cases\"}, {\"id\": 4, \"text\": \"INTRODUCTION: Small fiber neuropathy (SFN) is a heterogeneous group of disorders affecting thin myelinated A\\u00ce\\u00b4 and unmyelinated C fibers. Common symptoms include neuropathic pain and autonomic disturbances, and the typical clinical presentation is that of a length-dependent polyneuropathy, although other distributions could be present.\"}, {\"id\": 12, \"text\": \" Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. T\"}, {\"id\": 10, \"text\": \"mall fiber neuropathy (SFN) can be associated with autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (TS-HDS) antigen.\"}, {\"id\": 7, \"text\": \"Small fibre neuropathies are a heterogeneous group of disorders affecting thinly myelinated A\\u00ce\\u00b4-fibres and unmyelinated C-fibres. Although multiple causes of small nerve fibre degeneration have been reported, including via genetic mutations, the cause of small fibre neuropathy remains unknown in up to 50% of cases. The typical clinical presentation of small fibre neuropathy is that of a symmetrical, length-dependent polyneuropathy associated with sensory or autonomic symptoms.\"}, {\"id\": 11, \"text\": \"an the patients without SFN. Restless leg syndrome was also more frequently observed in patients with SFN, who had pain aggravated at rest that improved by moving.CONCLUSIONS: These findings are in favor of the sensitization of relatively spared large A\\u00ce\\u00b2-fibers and second-order\"}, {\"id\": 2, \"text\": \"Neuropathic pain is a characteristic feature of small fiber neuropathy (SFN), which in 18% of the cases is caused by genetic variants in voltage-gated sodium ion channels.\"}, {\"id\": 9, \"text\": \"Neuropathic pain (NP) is a main feature of Fabry disease (FD) as consequence of small fiber neuropathy. Restless legs syndrome (RLS) in FD was not described, but it is an important feature in other small fiber neuropathies\"}, {\"id\": 6, \"text\": \"SFN was defined by the presence of suggestive sensory painful symptoms with normal nerve conduction studies and abnormal neurophysiologic tests for small nerve fibers or a low intraepidermal nerve fiber density at skin biopsy.\"}, {\"id\": 0, \"text\": \"Small fiber neuropathy (SFN) is a peripheral nervous system disease due to affection of A-delta or C-fibers in a proximal, distal, or diffuse distribution. Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. Though uniform diagnostic criteria are unavailable, most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy.\"}, {\"id\": 5, \"text\": \"Small fibre neuropathy (SFN), a condition dominated by neuropathic pain, is frequently encountered in clinical practise either as prevalent manifestation of more diffuse neuropathy or distinct nosologic entity.\"}, {\"id\": 13, \"text\": \"SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life.\"}, {\"id\": 1, \"text\": \"Small-fiber neuropathy (SFN) is a disorder of thinly myelinated A\\u00ce\\u00b4 and unmyelinated C fibers. SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [12, 9, 10, 3, 11, 8, 5, 2, 6, 13, 1, 4, 0, 7]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \\u00e2\\u2030\\u00a550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \\u00e2\\u2030\\u00a51%), with disease progression on or after platinum-containing chemotherapy. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which gene therapies are under investigation for Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 5, \"text\": \" In relation to clinical trials, in the last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. \"}, {\"id\": 18, \"text\": \"The success of induced exon skipping has spawned a number of \\\"fusion therapies\\\", including vector-mediated dystrophin exon skipping and ex vivo viral delivery of splice-switching antisense molecules into myogenic stem cells, followed by implantation, which may address long term oligomer delivery issues.\"}, {\"id\": 6, \"text\": \"Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases\"}, {\"id\": 8, \"text\": \"So far, there is no effective treatment but new gene-based therapies are currently being developed with particular noted advances in using conventional gene replacement strategies, RNA-based approaches, or cell-based gene therapy with a main focus on Duchenne muscular dystrophy (DMD).\"}, {\"id\": 3, \"text\": \"gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations\"}, {\"id\": 4, \"text\": \"Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases.\"}, {\"id\": 12, \"text\": \"There are several promising genetic approaches, including viral delivery of the missing dystrophin gene, read-through of translation stop codons, exon skipping to restore the reading frame and increased expression of the compensatory utrophin gene.\"}, {\"id\": 1, \"text\": \"Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.\"}, {\"id\": 16, \"text\": \"Several promising gene therapies are currently under investigation. These include gene replacement, exon skipping, suppression of stop codons.\"}, {\"id\": 9, \"text\": \"Several new approaches to gene therapy for the muscular dystrophies involve oligonucleotides as targeting vectors.\"}, {\"id\": 10, \"text\": \"We recently showed that antisense oligoribonucleotide-mediated skipping of exon 46 efficiently induced dystrophin synthesis in cultured muscle cells from Duchenne muscular dystrophy patients carrying an exon 45 deletion.\"}, {\"id\": 13, \"text\": \"More recently, a promising gene editing tool referred to as CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD.\"}, {\"id\": 11, \"text\": \"These strategies include gene replacement with adeno-associated virus, exon skipping with antisense oligonucleotides, and mutation suppression with compounds that \\\"read through\\\" stop codon mutations.\"}, {\"id\": 7, \"text\": \"Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.\"}, {\"id\": 2, \"text\": \"The first viral-mediated gene transfer for any muscle disease was carried out at Columbus Children's Research Institute and Ohio State University for limb girdle muscular dystrophy type 2D, and the first viral-mediated trial of gene transfer for Duchenne muscular dystrophy is under way at the same institutions.\"}, {\"id\": 0, \"text\": \"Several clinical trials have recently demonstrated that oligonucleotide-based drugs induced targeted exon skipping in dystrophin pre-mRNA in Duchenne muscular dystrophy patients, resulting in novel expression of a truncated but functional isoform of the dystrophin protein.\"}, {\"id\": 14, \"text\": \"on gene replacement and gene/expression repair, including exon-skipping, vector-mediated gene therapy and cell therapy. Therapeutic strategies for different forms of muscular dystrophy are discussed, with an emphasis on \"}, {\"id\": 17, \"text\": \"rophy gene which abort dystrophin synthesis. We have explored a gene correction therapy aimed at restoration of the reading frame in Duchenne muscular\"}, {\"id\": 15, \"text\": \"Of all novel molecular interventions currently being investigated for Duchenne muscular dystrophy, perhaps the most promising method aiming to restore dystrophin expression to diseased cells is known as 'exon skipping' or splice-modulation, whereby antisense oligonucleotides eliminate the deleterious effects of DMD mutations by modulating dystrophin pre-messenger RNA splicing, such that functional dystrophin protein is produced.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 16, 13, 6, 10, 18, 0, 11, 12, 8, 1, 2, 4, 15, 7, 9, 3, 17, 14]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Does CIDEB mutation protect from liver disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"We also found that variants in CIDEB, which encodes a structural protein found in hepatic lipid droplets, had a protective effect. \"}, {\"id\": 1, \"text\": \"Germline Mutations in CIDEB and Protection against Liver Disease.\"}, {\"id\": 2, \"text\": \"CONCLUSIONS: Rare germline mutations in CIDEB conferred substantial protection from liver disease.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can you summarize the function of CDK9?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 7, \"text\": \"Cyclin-dependent kinases (CDKs) are a broad family of proteins involved in the cell cycle and transcriptional regulation. In this article, we explore the antitumoral activity of a novel proteolysis-targeting chimera (PROTAC) compound against CDK9\"}, {\"id\": 10, \"text\": \"This data suggests the involvement of Cdk9 in several physiological processes in the cell, the deregulation of which may be related to the genesis of transforming events, that may in turn lead to the onset of cancer.\"}, {\"id\": 13, \"text\": \" CDK9/Cyclin T1 kinase is a protein kinase, indirectly involved in the cell cycle progression in the form of transcription elongation\"}, {\"id\": 1, \"text\": \"Among various clinically validated kinases, the cyclin-dependent kinases (CDK) are one of the extensively studied drug targets for clinical developmen\"}, {\"id\": 5, \"text\": \"Cyclin-dependent kinase 9 (CDK9), with its cyclin T regulatory subunit, is a component of the positive transcription elongation factor b (P-TEFb) complex, which stimulates transcription elongation and also functions in co-transcriptional histone modification, mRNA processing, and mRNA export.\"}, {\"id\": 2, \"text\": \"Cdk9 function depends on its kinase activity and also on its regulatory units: the T-family cyclins and cyclin K. Recently, several studies confirmed the role of cdk9 in different cellular processes such as signal transduction, basal transcription, HIV-Tat- and MyoD-mediated transcription and differentiation.\"}, {\"id\": 8, \"text\": \"Cyclin Dependent Kinase 9 (CDK9) is one of the most important transcription regulatory members of the CDK family. In conjunction with its main cyclin partner-Cyclin T1, it forms the Positive Transcription Elongation Factor b (P-TEFb) whose primary function in eukaryotic cells is to mediate the positive transcription elongation of nascent mRNA strands, by phosphorylating the S2 residues of the YSPTSPS tandem repeats at the C-terminus domain (CTD) of RNA Polymerase II (RNAP II).\"}, {\"id\": 6, \"text\": \"Cdk9 is a member of the Cdc2-like family of kinases. Its cyclin partners are members of the family of cyclin T (T1, T2a and T2b) and cyclin K. The Cdk9/cyclin T complexes appear to be involved in regulating several physiological processes\"}, {\"id\": 4, \"text\": \"CDK9 is a prominent member of the transcriptional CDKs subfamily, a group of kinases whose function is to control the primary steps of mRNA synthesis and processing by eukaryotic RNA polymerase II. As a cyclin-dependent kinase, CDK9 activation in vivo depends upon its association with T-type cyclins to assemble the positive transcription elongation factor (P-TEFb).\"}, {\"id\": 12, \"text\": \"hese results suggest that, among other roles, cdk9/PITALRE plays a role not unlike cdk5 in the differentiation of certain cell types.\"}, {\"id\": 9, \"text\": \"Cyclin-dependent kinase 9 (CDK9), the kinase component of positive transcription elongation factor b (P-TEFb), is essential for transcription of most protein-coding genes by RNA polymerase II (RNAPII).\"}, {\"id\": 11, \"text\": \"CDK9 is a prominent member of the transcriptional CDKs subfamily, a group of kinases whose function is to control the primary steps of mRNA synthesis and processing by eukaryotic RNA polymerase II.\"}, {\"id\": 0, \"text\": \"We previously cloned a cdc2-related kinase, cdk9/PITALRE, that is able to phosphorylate the retinoblastoma protein i\"}, {\"id\": 3, \"text\": \"Cdk9/cyclin T1 belongs to the P-TEFb complex, and is responsible for the phosphorylation of the carboxyl-terminal domain (CTD) of the RNA Polymerase II, thus promoting general elongation.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [6, 0, 12, 13, 1, 7, 3, 2, 10, 11, 5, 8, 4, 9]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'How does RBM24 control QT interval?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Thus, our data suggest that RBM24 is a critical regulator of CaMKII\\u00ce\\u00b4 to control the cardiac QT interval, highlighting the key role of splicing regulation in cardiac rhythm.\"}, {\"id\": 1, \"text\": \"RBM24 controls cardiac QT interval through CaMKII\\u00ce\\u00b4 splicing.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Functional variability among boys with Duchenne muscular dystrophy (DMD) is well recognised and complicates interpretation of clinical studies. We hypothesised that boys with DMD could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the North Star Ambulatory Assessment (NSAA) total score.\"}, {\"id\": 6, \"text\": \"The boys were evaluated with standardized assessments at the screening and baseline visits at 32 sites in 5 countries (US, UK, Canada, Italy, Germany). Assessments included timed rise from floor, timed 10\\u00e2\\u20ac\\u00afm walk/run, six-minute walk distance, North Star Ambulatory Assessment (NSAA) and forced vital capacity (FVC). Mean age at baseline was 5.9 years (range 4.1-8.1 years). Test-retest reliability was high for functional assessments, regardless of time lag between assessments (up to 90 days) and for the majority of age groups. Correlations were strong among the functional measures and timed tests, less so with FVC.\"}, {\"id\": 1, \"text\": \"measurement. All analyses were performed using the Rasch Unidimensional Measurement Model.RESULTS: Overall, Rasch analysis supported the NSAA as being a reliable (high Person Separation Index of 0.91) and valid (good targeting, little misfit, no reversed thresholds) measure of ambul\"}, {\"id\": 2, \"text\": \"The North Star Ambulatory Assessment is a functional scale specifically designed for ambulant boys affected by Duchenne muscular dystrophy (DMD).\"}, {\"id\": 5, \"text\": \"hese exploratory analyses reveal additional approaches to interpreting the NSAA data beyond just change in NSAA total score. These observations also highlight the importance of reporting items as \\\"not obtainable\\\" for a patient with a temporary/transient physical disability that impacts their ability to perform the NSAA test.\"}, {\"id\": 9, \"text\": \" North Star Ambulatory Assessment in Brazilian Portuguese is a reliable and valid instrument to measure functional capacity in boys with Duchenne muscular dystrophy.\"}, {\"id\": 8, \"text\": \"The results showed a significant difference in the NSAA score between the deletion and nonsense groups at the age of 3 years (P\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.04).\"}, {\"id\": 3, \"text\": \"We hypothesised that boys with DMD could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the North Star Ambulatory Assessment (NSAA) total score.\"}, {\"id\": 7, \"text\": \"The North Star Ambulatory Assessment (NSAA) is a validated 17-item functional rating scale and widely used to assess motor function in boys with Duchenne muscular dystrophy (DMD).\"}, {\"id\": 4, \"text\": \"INTRODUCTION: The North Star Ambulatory Assessment (NSAA) tool is a key instrument for measuring clinical outcomes in patients with Duchenne muscular dy\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [8, 6, 7, 5, 1, 3, 4, 2, 9, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the mechanism of action of rilzabrutinib?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Herein, we describe the design of covalent reversible BTK inhibitors and the discoveries of PRN473 (11) and rilzabrutinib (PRN1008, 12). \"}, {\"id\": 2, \"text\": \"Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).\"}, {\"id\": 3, \"text\": \"Ongoing trials include new B-cell/plasma-cell targeting agents such as the Bruton tyrosine kinase inhibitors ibrutinib and rilzabrutinib, and the anti-CD38 MoAbs daratumumab and its analogue isatuximab. \"}, {\"id\": 1, \"text\": \"This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 2, 0, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the  types/categories of adult diffuse gliomas.' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 15, \"text\": \" The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.\"}, {\"id\": 14, \"text\": \"This has resulted in a major revision of the WHO classification, which is now for adult diffuse glioma centered around isocitrate dehydrogenase (IDH) and 1p/19q diagnostics.\"}, {\"id\": 9, \"text\": \"This review briefly discusses two tumor types: astrocytoma, IDH-mutant, and oligodendroglioma, IDH-mutant and 1p/19q codeleted, with emphasis on relevant changes in their classification and defining molecular genetic alterations.\"}, {\"id\": 3, \"text\": \"Adult gliomas are most often infiltrative. The World Health Organization (WHO) has classed them into three major groups according to the presomptive cell of origin: astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Depending on the presence or absence of a small number of signs of anaplasia (mitosis, nuclear atypia, cell density, microvascular proliferation and necrosis) the WHO distinguishes grade II (LGG), III (anaplastic), and IV (glioblastomas, GBM).\"}, {\"id\": 12, \"text\": \"C\\u00e2\\u20ac\\u2030>\\u00e2\\u20ac\\u20300.5, k\\u00e2\\u20ac\\u2030>\\u00e2\\u20ac\\u20300.6, p\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.001). IBGS type-I, type-II, and type-III gliomas had good specificity in identifying IDHmut 1p19q-codel oligodendroglioma (training - 97%, validation - 85%); IDHmut 1p19q non-codel astrocytoma (training - 80%, validation - 85.9%); and IDHwt glioblastoma (training - 76.5%, validation- 87.3%) respectively (p-value\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.01).CONCLUSIONS: Imaging-based stratification of adult diffuse gliomas predicted patient survival and correlate\"}, {\"id\": 1, \"text\": \"A four-tiered WHO grading scheme has been successfully applied to a spectrum of diffusely infiltrative astrocytomas, but it is not fully applicable to other gliomas, including oligodendrogliomas and ependymomas.\"}, {\"id\": 11, \"text\": \"O classification, five main molecular subgroups of adult diffuse gliomas can be distinguished based on the 1p/19q codeletion, isocitrate dehydrogenase (IDH), and histone H3.3 mutation status. In the future, this cla\"}, {\"id\": 7, \"text\": \" According to the 2021 World Health Organization classification, the three risk types included (1) low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant, and 1p/19q-codeleted; (2) intermediate-risk, expecting astrocytoma, IDH-mutant; and (3) high-risk, expecting glioblastoma, IDH-wildtype.\"}, {\"id\": 5, \"text\": \" Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype\"}, {\"id\": 2, \"text\": \"vide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma. The T2-\"}, {\"id\": 6, \"text\": \"Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype.\"}, {\"id\": 4, \"text\": \"A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.\"}, {\"id\": 20, \"text\": \"This improves diagnostic accuracy and prognostication: oligo-astrocytoma no longer exists as a clinical entity; isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted oligodendroglioma is a smaller category with better prognosis; IDH wild-type 'low-grade' glioma has a much poorer prognosis; and glioblastoma is divided into IDH mutant (with an better prognosis than pre-2016 glioblastoma) and IDH wild type (with a poorer prognosis).\"}, {\"id\": 19, \"text\": \"Recent genetic studies have revealed that the major categories of gliomas, such as circumscribe astrocytomas, infiltrating astrocytomas/oligodendrogliomas, and glioblastoma, roughly correspond to major genetic alterations, including isocitrate dehydrogenases (IDHs) 1/2 mutations, TP53 mutations, co-deletion of chromosome arms 1p/19q, and BRAF mutation/fusion.\"}, {\"id\": 8, \"text\": \"thogenesis and prognosis. Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocitrate dehydrogenase (IDH) mutant; oligodendroglioma, IDH mutant and 1p/19q codeleted; and gl\"}, {\"id\": 17, \"text\": \"In the new WHO classification 2021, adult-type diffuse astrocytic gliomas subdivide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma.\"}, {\"id\": 10, \"text\": \"include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype. This r\"}, {\"id\": 16, \"text\": \"Since brainstem biopsies are rarely performed, these tumours are commonly classified according to their MR imaging characteristics into 4 subgroups: (a) diffuse intrinsic low-grade gliomas, (b) enhancing malignant gliomas, (c) focal tectal gliomas and (d) exophytic gliomas/other subtypes.\"}, {\"id\": 13, \"text\": \"The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.\"}, {\"id\": 18, \"text\": \"hese changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the ma\"}, {\"id\": 0, \"text\": \"ssion, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopatho\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 7, 6, 4, 8, 9, 16, 12, 17, 19, 20, 1, 14, 13, 15, 0, 2, 10, 18, 11, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Engineered T cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor (CAR)-T cell therapies now approved for the treatment of B cell malignancies based on their unprecedented efficacy in clinical trials. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is golodirsen effective for the treatment of Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"To date, four PMOs, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the FDA for the treatment of DMD.\"}, {\"id\": 1, \"text\": \"This study provides evidence for golodirsen biologic activity and long-term safety in a declining DMD population and suggests functional benefit versus external controls. \"}, {\"id\": 0, \"text\": \"Golodirsen increased dystrophin protein (16.0-fold; P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.001) and exon skipping (28.9-fold; P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.001).\"}, {\"id\": 2, \"text\": \"This article summarizes the milestones in the development of golodirsen leading to this first approval for DMD.\"}, {\"id\": 4, \"text\": \"Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping. \"}, {\"id\": 5, \"text\": \"n December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 2, 5, 3, 0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is Baricitinib effective for Alopecia Areata?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. \"}, {\"id\": 1, \"text\": \"Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. \"}, {\"id\": 3, \"text\": \"Two Phase 3 Trials of Baricitinib for Alopecia Areata.\"}, {\"id\": 2, \"text\": \"CONCLUSIONS: In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0, 3, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Anemia is not associated with chronic kidney failure' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 18, \"text\": \" The high prevalence of anemia in chronic kidney disease is explained by a combination of erythropoietin and iron deficiency.\"}, {\"id\": 28, \"text\": \"Correction of the anemia with erythropoietin and intravenous iron led to a marked improvement in patients' functional status and their cardiac function, and to a marked fall in the need for hospitalization and for high-dose diuretics; renal function usually improved or at least stabilized.\"}, {\"id\": 1, \"text\": \"Use of EPOGEN for treatment of anemia associated with chronic renal failure.\"}, {\"id\": 9, \"text\": \"Cardiovascular disease remains the major cause of mortality in patients with end stage renal disease (ESRD). The pathophysiology of cardiac dysfunction in ESRD is complex and not fully understood. However, it appears that the two major determinants of left ventricular (LV) hypertrophy and dysfunction are anemia and hypertension, both of which are very common in ESRD patients.\"}, {\"id\": 20, \"text\": \"We call this interrelationship between congestive heart failure, chronic kidney insufficiency, and anemia the Cardio-Renal Anemia syndrome.\"}, {\"id\": 23, \"text\": \"End stage renal disease (ESRD) invariably leads to anemia which has been mainly attributed to compromised release of erythropoietin from the defective kidneys with subsequent impairment of erythropoiesis.\"}, {\"id\": 7, \"text\": \"This study was to explore the clinical efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection (recombinant human erythropoietin injection, rHuEPO) for the treatment of anemia associated with chronic kidney failure\"}, {\"id\": 27, \"text\": \" This analysis was conducted to evaluate whether anemia is a risk factor for kidney function decrease in patients with heart failure.\"}, {\"id\": 11, \"text\": \"In patients with CKD, anemia is often caused by decreased erythropoietin production relative to hemoglobin levels.\"}, {\"id\": 25, \"text\": \"Anemia in chronic renal failure is predominantly caused by diminished erythropoietin synthesis by diseased kidneys.\"}, {\"id\": 5, \"text\": \"The anemia is very often associated with chronic kidney disease (CKD).\"}, {\"id\": 24, \"text\": \"Anemia as a risk factor for kidney function decline in individuals with heart failure.\"}, {\"id\": 22, \"text\": \"The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions.\"}, {\"id\": 6, \"text\": \"The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardio renal anemia syndrome.\"}, {\"id\": 3, \"text\": \"BACKGROUND: Kidney failure is known to cause anemia, which is associated with a higher risk of cardiac failure an\"}, {\"id\": 15, \"text\": \"Anemia is one of the most characteristic and visable manifestations of chronic renal failure. Investigators in the past decade have provided a better understanding of this anemia. The etiology of the anemia of chronic renal failure has three facets: first is reduced erythropoietin production by damaged kidneys; second is the presence of inhibitors to red blood cell (RBC) production in uremic serum; and third is red blood cell hemolysis.\"}, {\"id\": 21, \"text\": \"We infer that impaired utilization of iron may be a significant factor in the anemia of chronic renal failure.\"}, {\"id\": 19, \"text\": \"BACKGROUND: Kidney failure causes anemia and is associated with a very high risk of coronary heart di\"}, {\"id\": 16, \"text\": \"Anemia is the most common hematologic complication in end-stage renal disease (ESRD). It is ascribed to decreased erythropoietin production, shortened red blood cell (RBC) lifespan, and inflammation.\"}, {\"id\": 30, \"text\": \" In conclusion, anemia is associated with a rapid decrease in kidney function in patients with heart failure, particularly in those with underlying CKD.\"}, {\"id\": 29, \"text\": \"Anemia is a major problem in patients with chronic kidney insufficiency.\"}, {\"id\": 17, \"text\": \"Anaemia is a common manifestation ofa chronic kidney failure. \"}, {\"id\": 14, \"text\": \"NGAL, also known as lipocalin 2, is a stress protein located on the cell surface that is known for its involvement in iron transport. This study is aimed to evaluate the correlation between the iron profile and NGAL concentration in serum among chronic kidney disease patients under dialysis in order to find its diagnostic value with regards to iron deficiency anaemia (IDA).\"}, {\"id\": 2, \"text\": \" Partial, but not complete, correction of anemia is associated with improved outcomes in patients with CKD.\"}, {\"id\": 0, \"text\": \"While iron deficiency is often stated as a cause of anemia in chronic renal failure prior to end-stage renal disease, its relative contribution is debated.\"}, {\"id\": 8, \"text\": \"Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review.\"}, {\"id\": 4, \"text\": \"Clearly more work is needed to clarify the relationship between anemia, CKD and CHF.\"}, {\"id\": 26, \"text\": \" Heart failure, anemia and chronic renal failure are mutually related.\"}, {\"id\": 10, \"text\": \"The hormone deficiency that underlies anemia in chronic kidney failure can now be corrected\"}, {\"id\": 12, \"text\": \"BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin\"}, {\"id\": 31, \"text\": \"Chronic kidney disease (CKD) is a widespread health problem in the world and anaemia of renal origin is a common problem.\"}, {\"id\": 13, \"text\": \" Many advanced chronic kidney disease patients have both anemia and chronic heart failure.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [7, 17, 10, 20, 29, 28, 5, 6, 0, 25, 21, 19, 3, 22, 12, 11, 4, 1, 26, 8, 2, 18, 13, 30, 27, 24, 23, 31, 16, 15, 9, 14]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the estimated reduction in time when using online genetic counseling?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \" trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u2030.001 for daily predn\"}, {\"id\": 2, \"text\": \"Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival.\"}, {\"id\": 0, \"text\": \"Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.\"}, {\"id\": 3, \"text\": \"Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u2030.001 for daily prednisone vs intermittent prednisone using a global test; P\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u2030.017 for daily deflazacort vs intermittent prednisone using a global test)\"}, {\"id\": 4, \"text\": \"Evidence from randomized clinical trials, prospective studies, meta-analyses, and post-hoc analyses suggests that patients receiving deflazacort experience similar or slower rates of functional decline compared with those receiving prednisone/prednisolone. \"}, {\"id\": 5, \"text\": \"Among patients with Duchenne muscular dystrophy, treatment with daily prednisone or daily deflazacort, compared with intermittent prednisone alternating 10 days on and 10 days off, resulted in significant improvement over 3 years in a composite outcome comprising measures of motor function, pulmonary function, and satisfaction with treatment\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 5, 2, 4, 0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the targets of Mosunetuzumab?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"BACKGROUND: Mosunetuzumab is a CD20\\u00e2\\u20ac\\u2030\\u00c3\\u2014\\u00e2\\u20ac\\u2030CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. I\"}, {\"id\": 0, \"text\": \"They combine two different monospecific antigen-binding regions that target CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab) format. The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published.\"}, {\"id\": 1, \"text\": \"However, several CD20 \\u00c3\\u2014 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab emerged recently. \"}, {\"id\": 3, \"text\": \"Mosunetuzumab (Lunsumio\\u00c2\\u00ae), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 3, 2, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is anaphylaxis a results of mast cell activation?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 25, \"text\": \"Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome.\"}, {\"id\": 37, \"text\": \" types. Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in diff\"}, {\"id\": 18, \"text\": \" When there is activation of mast cells and basophils in anaphylaxis, chemical mediators are detectable.\"}, {\"id\": 14, \"text\": \"Elevated mast cell mediators such as tryptase and histamine have been reported during episodes, and mast cells are considered the primary cells responsible for driving anaphylaxis in humans.\"}, {\"id\": 8, \"text\": \"Anaphylaxis is a rapidly evolving, acute, life-threatening reaction that occurs rapidly on contact with a trigger. Anaphylaxis is classically defined as an allergen-driven process that induces specific IgE and the activation of mast cells and basophils through the cross-linking of IgE receptors.\"}, {\"id\": 36, \"text\": \"Anaphylaxis is a life-threatening syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation.\"}, {\"id\": 17, \"text\": \" A precondition for the unfolding of the anaphylactic shock is the secretion of inflammatory mediators from mast cells in response to an allergen, mostly through activation of the cells via the IgE-dependent pathway.\"}, {\"id\": 39, \"text\": \"Anaphylaxis results from severe systemic mast cell activation. In addition to IgE-mediated and physical triggers, it may occur with a clonal mast cell\"}, {\"id\": 43, \"text\": \"Idiopathic anaphylaxis involves mast cell activation (acutely elevated urine histamine or serum tryptase) and activated lymphocytes.\"}, {\"id\": 13, \"text\": \"During the IgE-mediated anaphylactic reaction mast cells release proteases such as tryptase, histamine and vasoactive mediators\"}, {\"id\": 27, \"text\": \"For half a century, it has been known that the mast cell is the cell responsible for the majority of anaphylactic events. Its mediators, taken as a whole, are capable of producing all of the clinical manifestations of these events.\"}, {\"id\": 3, \"text\": \"Extensive activation of mast cells is the major switch that triggers systemic anaphylaxis, resulting in the subsequent release of anaphylactic mediators into circulation.\"}, {\"id\": 6, \"text\": \"r, Ang-1's function in mast cell activation and anaphylaxis diseases is unknown. The results of our study suggest that Ang-1 decreased lipopolysacchar\"}, {\"id\": 31, \"text\": \"Mast cells are important effector cells in allergic inflammatory reactions. The aggregation of the high-affinity IgE receptor (FcepsilonRI) on the surface of mast cells initiates a complex cascade of signaling events that ultimately leads to the release of various mediators involved in allergic inflammation and anaphylactic reactions\"}, {\"id\": 22, \"text\": \"s not affected. Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence \"}, {\"id\": 33, \"text\": \"\\u00ce\\u00b5RI-mediated mast cell activation and anaphylaxis that were insensitive to U0126 or activator 5-aminoimidazole-4-carboxamide-1-\\u00ce\\u00b2-4-ribofuranoside, suggesting that the suppression of Fc\\u00ce\\u00b5RI signals by the inhibition of the ERK1/2 pathway relies largely on AMPK activation. ERK1/2 controlled AMPK activity by regulating its subcellul\"}, {\"id\": 11, \"text\": \"ol subjects. The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system activation, and bradykin\"}, {\"id\": 16, \"text\": \"In this chapter, we will describe the mechanisms of mast cell (and basophil) activation in anaphylaxis, with a focus on IgE-dependent activation, which is thought to be responsible for most examples of antigen-induced anaphylaxis in humans.\"}, {\"id\": 4, \"text\": \"Some usual clinical manifestations in anaphylaxis, such as angioedema or hypotension, or other less common, such as metrorrhagia, may be explained by the direct effect of the activation of the coagulation and contact system driven by mast cell mediators.\"}, {\"id\": 21, \"text\": \"Systemic anaphylaxis arises when mast cells, possibly along with other cell types, are provoked to secrete mediators that evoke a systemic response.\"}, {\"id\": 28, \"text\": \"Earlier mast cells were only known for their important role in the type 1 allergic reactions (i.e. anaphylaxis or some contact hypersensitivity reactions) \"}, {\"id\": 0, \"text\": \" Although the mast cell is considered the major effector cell during acute allergic reactions, more recent studies indicate a potentially important and specific role for basophils and their migration which occurs rapidly upon allergen challenge in humans undergoing anaphylaxis.\"}, {\"id\": 10, \"text\": \"ted that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK). However, little is known about the rela\"}, {\"id\": 24, \"text\": \" types. Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in different mast cell models, and the open questions in the field which remain to be a\"}, {\"id\": 19, \"text\": \"arepsilonRI) on mast cells. However, the regulatory mechanism of mast cell activation i\"}, {\"id\": 12, \"text\": \"Anaphylaxis results from severe systemic mast cell activation.\"}, {\"id\": 2, \"text\": \"Anaphylaxis is a rapidly developing, life-threatening, generalized or systemic allergic reaction that is classically elicited by antigen crosslinking of antigen-specific IgE bound to the high-affinity IgE receptor Fc\\u00ce\\u00b5RI on mast cells and basophils.\"}, {\"id\": 26, \"text\": \"Anaphylactic Degranulation of Mast Cells: Focus on Compound Exocytosis.\"}, {\"id\": 38, \"text\": \"Mast cell activation syndromes presenting as anaphylaxis.\"}, {\"id\": 5, \"text\": \"PURPOSE OF REVIEW: Mast cell activation syndrome (MCAS) and anaphylaxis are the result of a spontaneous or triggered pathological degranulation of mast cells (MCs) and might have as substrate normal or pathological MCs (increased burden, aberrant MCs or both).RECENT FINDINGS: This review summarizes the most recent evidence on immunoglobulin E (IgE)-mediated and non IgE-mediated mechanisms underlying MC activation and degranulation and highlights the importance of standa\"}, {\"id\": 32, \"text\": \"Acute anaphylaxis to small molecule drugs is largely considered to be antibody-mediated with immunogloblin E (IgE) and mast cell activation being key.\"}, {\"id\": 34, \"text\": \"phylaxis in 22-49%. In addition, monoclonal mast cell activation syndrome has been described presenting with anaphylaxis, especially in patients with \"}, {\"id\": 35, \"text\": \"ol subjects. The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system\"}, {\"id\": 30, \"text\": \" Beyond IgE-mediated activation of mast cells/basophils, further mechanisms are involved in the occurrence of anaphylaxis.\"}, {\"id\": 40, \"text\": \"Human mast cells, by elaborating vasoactive mediators and cytokines, are the primary effector cells of anaphylaxis.\"}, {\"id\": 7, \"text\": \"Histamine and other deleterious inflammatory mediators promote vascular permeability and smooth muscle contraction; they are readily released from sensitized mast cells and basophils challenged with antigen. Anaphylaxis may be triggered by a variety of antigens including insect and reptile venom, a variety of drugs, vaccines, and food\"}, {\"id\": 20, \"text\": \"In IgE-dependent and other examples of anaphylaxis, tissue mast cells and circulating basophilic granulocytes (basophils) are thought to represent major (if not the major) sources of the biologically active mediators that contribute to the pathology and, in unfortunate individuals, fatal outcome, of anaphylaxis.\"}, {\"id\": 15, \"text\": \"s not affected. Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence of PK-treatment. Inhibition of \"}, {\"id\": 42, \"text\": \"Anaphylaxis results from the massive activation of the mast cells (MCs).\"}, {\"id\": 29, \"text\": \"Anaphylaxis results from severe systemic mast cell activation. In addition to IgE-mediated and physical triggers, it may occur with a clonal mast cell disease and in an idiopathic fashion without clear provoking factors.\"}, {\"id\": 9, \"text\": \"w clinical entities, such as the \\u00ce\\u00b1-gal anaphylaxis. Anaphylaxis results from the massive activation of the mast cells (MCs). Thus, it is also necessar\"}, {\"id\": 1, \"text\": \"ed in the amplification of the mast cell response during anaphylaxis are unclear. Mouse models of anaphylaxis demonstrate the critical involvement of \"}, {\"id\": 23, \"text\": \"phylaxis in 22-49%. In addition, monoclonal mast cell activation syndrome has been described presenting with anaphylaxis, especially in patients with hymenopter\"}, {\"id\": 41, \"text\": \"When there is activation of mast cells and basophils in anaphylaxis, chemical mediators are detectable.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [31, 13, 7, 28, 12, 20, 38, 5, 14, 16, 36, 4, 43, 41, 21, 42, 40, 0, 32, 26, 25, 17, 30, 18, 3, 1, 34, 35, 37, 9, 10, 15, 23, 11, 24, 19, 22, 6, 33, 39, 27, 29, 2, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'On which two clinical trials was the approval of Keytruda based?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients randomized to pembrolizumab compared with chemotherapy. In KEYNOTE-024, patients with previously untreated mNSCLC who received pembrolizumab (200 mg intravenously [IV] every 3 weeks) had a statistically significant improvement in OS (hazard ratio [HR] 0.60; 95% confidence interval [CI]: 0.41-0.89; p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u2030.005), and significant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u2030.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing chemotherapy received pembrolizumab IV 2 mg/kg, 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Viltolarsen restores the reading frame of the DMD gene by skipping \\u00c2\\u00a0exon 53\\u00c2\\u00a0and produces a truncated but functional form of dystrophin. \"}, {\"id\": 0, \"text\": \"Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\u00c2\\u00a0for the treatment of Duchenne muscular dystrophy (DMD)\"}, {\"id\": 2, \"text\": \"After showing hopeful results in pre-clinical trials and several clinical trials across North America and Japan, it received US Food and Drug Administration (FDA) approval for DMD\\u00c2\\u00a0in 2020.\"}, {\"id\": 4, \"text\": \"esulting in an absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. Herein, long-term (>2 years) functional outcomes in viltolarsen treated pati\"}, {\"id\": 5, \"text\": \"Viltolarsen restores the reading frame of the DMD gene by skipping \\u00c2\\u00a0exon 53\\u00c2\\u00a0and produces a truncated but functional form of dystrophin.\"}, {\"id\": 3, \"text\": \"ucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1, 2, 5, 3, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is Wilkie's syndrome?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Superior mesenteric artery syndrome (SMA syndrome) or Wilkie's syndrome is a rare etiology of duodenal obstruction due to compression of the third portion of the duodenum between the superior mesenteric artery and the aorta. \"}, {\"id\": 1, \"text\": \"Introduction Superior mesenteric artery (SMA) or Wilkie's syndrome is a rare condition arising due to compression of the third part of the duodenum between the abdominal aorta and the superior mesenteric artery.\\u00c2\\u00a0\"}, {\"id\": 5, \"text\": \"BACKGROUND: The superior mesenteric artery (SMA) syndrome, also known as Wilkie's syndrome, is one of the rarest causes of small bowel obstruction.\"}, {\"id\": 0, \"text\": \"Superior mesenteric artery syndrome, or Wilkie's syndrome, is an unexpected cause of upper gastrointestinal tract obstruction. \"}, {\"id\": 3, \"text\": \"INTRODUCTION: Wilkie's Syndrome, also known as Superior Mesenteric Artery Syndrome (SMAS), is a rare cause of bowel obstruction that can contribute to vague abdominal symptoms on clinical presentation.\"}, {\"id\": 4, \"text\": \"BACKGROUND Nutcracker syndrome and Wilkie's syndrome are rare vascular diseases due to the abnormal course of the superior mesenteric artery originating from the abdominal aorta with reduced angle (<22\\u00c2\\u00b0) and consequent compression of the left renal vein (nutcracker) and duodenum (Wilkie). \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 4, 3, 0, 1, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is a PROTAC?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 31, \"text\": \"Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of one ligand that binds to a protein of interest (POI) and another that can recruit an E3 ubiquitin ligase. The chemically-induced proximity between the POI and E3 ligase results in ubiquitination and subsequent degradation of the POI by the ubiquitin-proteasome system (UPS).\"}, {\"id\": 3, \"text\": \"Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets.\"}, {\"id\": 6, \"text\": \"Proteolysis-targeting chimeras (PROTACs) degrade target proteins by engaging the ubiquitin-proteasome system. Assays detecting target-PROTAC-E3 ligase\"}, {\"id\": 23, \"text\": \"We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor.\"}, {\"id\": 16, \"text\": \"PROTACs are the heterobifunctional nano molecules with size range of about 10 nanometres find application to eliminate the protein complexes formed by protein-protein interaction through large and flat surface generally defined as \\\"undruggable\\\" in conventional drug delivery system, which include around 85 % of proteins present in humans, suggesting their wide application in the field of drug development.\"}, {\"id\": 11, \"text\": \"uary 2013 through June 2020. Only English-language patent applications with exemplified PROTACs reported to degrade a target protein(s) were deemed in scope, and the definition of 'PROTAC' was restricted to a bifunctional molecule which contains a discrete binding element for a specific degradation target(s), as well as a separate discrete E3 ligase-binding moiety.EXPERT OPINION: Delivering on the enormous potential of PROTACs will require the development of PROTAC medicines that are differentiate\"}, {\"id\": 4, \"text\": \"Here we describe the design of a novel PROTAC (proteolysis targeting chimeric molecule) capable of simultaneously inducing the degradation of the X-protein, and antagonizing its function.\"}, {\"id\": 36, \"text\": \"Proteolysis targeting chimeras (PROTACs) are molecules that induce protein degradation via formation of ternary complexes between an E3 ubiquitin ligase and a target protein. \"}, {\"id\": 26, \"text\": \"Proteolysis Targeting Chimeras (PROTACs) are a new promising class of small molecules that can effectively direct specific proteins to proteasomal degradation.\"}, {\"id\": 24, \"text\": \"PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-degradation strategy that has emerged in recent years.\"}, {\"id\": 37, \"text\": \"Proteolysis-targeting chimeras (PROTACs) are small molecules that specifically link E3 ubiquitin ligases to proteins of interest to mediate targeted ubiquitination and degradation.\"}, {\"id\": 33, \"text\": \"We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degradation of CRBN.\"}, {\"id\": 29, \"text\": \"Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (PROTAC) results in a compound that induces degradation of FLT-3 ITD mutant at low nanomolar concentrations.\"}, {\"id\": 13, \"text\": \"Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3). Upon binding to the POI, the PROTAC can recruit E3 for POI ubiquitination, which is subjected to proteasome-mediated degradation.\"}, {\"id\": 17, \"text\": \"Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system.\"}, {\"id\": 20, \"text\": \"Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies.\"}, {\"id\": 8, \"text\": \"Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation.\"}, {\"id\": 32, \"text\": \" PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ability to selectively degrade target proteins.\"}, {\"id\": 14, \"text\": \"PROteolysis-TArgeting Chimera (PROTAC) is an innovative strategy that takes advantage by the cell's own Ubiquitin-Proteasome System (UPS).\"}, {\"id\": 19, \"text\": \"Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand.\"}, {\"id\": 22, \"text\": \"Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of interest (POI) induces its ubiquitination-based proteolysis by recruiting an E3 ligase.\"}, {\"id\": 34, \"text\": \"Proteolysis targeting chimeras (PROTACs) are hetero-bifunctional molecules that could simultaneously bind to the target protein and the E3 ubiquitin ligase, thereby leading to selective degradation of the target protein.\"}, {\"id\": 27, \"text\": \"Development of proteolysis targeting chimeras (PROTACs) is emerging as a promising strategy for targeted protein degradation. However, the drug develo\"}, {\"id\": 38, \"text\": \"A parallel, one-pot assembly approach to proteolysis targeting chimeras (PROTACs) is demonstrated utilizing activated esters generated in situ, and traceless Staudinger ligation chemistry.\"}, {\"id\": 1, \"text\": \"Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation.\"}, {\"id\": 5, \"text\": \"Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent degradation of protein of interest.\"}, {\"id\": 12, \"text\": \"We have previously reported a library of proteolysis targeting chimeras (PROTACs) incorporating a benzamide-based HDAC ligand (from CI-994), with an alkyl linker and ligand for the von Hippel-Lindau (VHL) E3 ubiquitin ligase that degrade HDAC1-3 at submicromolar concentrations.\"}, {\"id\": 9, \"text\": \"PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in re\"}, {\"id\": 10, \"text\": \"PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in recent years.\"}, {\"id\": 35, \"text\": \"Targeted protein degradation using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery. PROTACs mediate the degradation of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degradation by the 26S proteasome.\"}, {\"id\": 39, \"text\": \"A technology was developed known as Protac (Proteolysis Targeting Chimeric Molecule) that acts as a bridge, bringing together the SCF ubiquitin ligase with a protein target, resulting in its ubiquitination and degradation.\"}, {\"id\": 21, \"text\": \"We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8).\"}, {\"id\": 28, \"text\": \"Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteaso\"}, {\"id\": 2, \"text\": \"Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug discovery paradigm which has been widely used as biological tools and medicinal molecules with the potential of clinical application value.\"}, {\"id\": 18, \"text\": \"Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent \"}, {\"id\": 0, \"text\": \"Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel ther\"}, {\"id\": 30, \"text\": \"INTRODUCTION: PROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the t\"}, {\"id\": 15, \"text\": \"Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule c\"}, {\"id\": 7, \"text\": \"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.\"}, {\"id\": 25, \"text\": \"PROTACs (proteolysis targeting chimeras) emerge as a powerful class of therapeutic modalities, which rely on induced protein-protein interactions between the proteins of interest (POIs) and E3 ubiquitin ligases to aid the degradation of POIs by the ubiquitin-proteasome system (UPS).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [24, 31, 36, 29, 5, 1, 14, 4, 23, 37, 12, 21, 7, 8, 16, 30, 39, 11, 34, 25, 33, 26, 32, 28, 18, 0, 15, 9, 3, 22, 20, 10, 2, 6, 19, 38, 27, 13, 35, 17]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can the concept of digital twins be applied in Precision Nutrition?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"We herein discuss how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a \\\"virtual digital twin,\\\" which could serve to guide nutrition in a personalized manner.\"}, {\"id\": 0, \"text\": \"The \\\"Virtual Digital Twins\\\" Concept in Precision Nutrition\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the mechanism of action of Teclistamab?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.\"}, {\"id\": 2, \"text\": \"BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen \\u00c3\\u2014 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.\"}, {\"id\": 1, \"text\": \"The bispecific antibodies teclistamab (BCMA\\u00c3\\u2014CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\\u00c3\\u2014CD3) are in clinical development as therapies for MM. \"}, {\"id\": 3, \"text\": \"Teclistamab (TECVAYLI\\u00c2\\u00ae), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 2, 1, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'The diagnosis of cholestasis is based on the elevations seen in what liver function tests?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 10, \"text\": \"diagnosis of liver disease when conventional liver function test such as SGOT, alkaline phosphatase, bilirubin and albumin are still normal. Serum bile acid determinations have been shown to be particularly useful in the diagnosis of alcoholic liver disease, drug-induced liver disease, viral hepatitis and cholestasis of intra- and extrahepatic origin. \"}, {\"id\": 1, \"text\": \" The liver function test revealed elevated levels of serum total bile acids, bilirubin, and transaminases; however, the \\u00ce\\u00b3-glutamyl transferase level was norma\"}, {\"id\": 3, \"text\": \" bilirubin proved to be the best laboratory test in differentiating patients (p=0.001 vs. alkaline phosphatase, p<0.001 vs. alanine aminotransferase and p<0.001 vs. gamma-glutamyltransferase). With a plasma bilirubin cutoff value of 145 micromol/L, four out of five patients were categorized \"}, {\"id\": 7, \"text\": \"Cholestasis of pregnancy is the commonest liver disease unique to pregnancy and is characterized by pruritus in the mother in late pregnancy, without any skin rashes. This is accompanied by an elevation of the serum bile acids. \"}, {\"id\": 8, \"text\": \"ase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. Th\"}, {\"id\": 2, \"text\": \"Plasma alkaline phosphatase, gamma-glutamyltransferase, alanine aminotransferase and bilirubin values were determined in the morning before ERCP\"}, {\"id\": 0, \"text\": \"Cholestasis is usually suspected clinically when a patient presenting with jaundice or pruritus is found to have an elevation in serum alkaline phosphatase activity disproportionate to increases in serum aminotransferase levels.\"}, {\"id\": 5, \"text\": \"CONCLUSIONS: Plasma bilirubin seems to be the best liver function test in distinguishing patients with malignant bile duct strictures from those with bile duct stones. This routine test should receive more attention in clinical decision-making than has previously been given.\"}, {\"id\": 9, \"text\": \"The biochemical parameters traditionally used for the assessment of extrahepatic cholestasis, AP, GGT, and bilirubin, do not support the diagnosis of intrahepatic cholestasis caused by cirrhosis.\"}, {\"id\": 4, \"text\": \"Intrahepatic cholestasis of pregnancy (ICP) is the most frequent pregnancy-specific liver disease. It is characterized by pruritus and an accompanying elevation of serum bile acid concentrations and/or alanine aminotransferase (ALT), which are the key parameters in the diagnosis.\"}, {\"id\": 6, \"text\": \"Plasma bilirubin (p<0.001), alkaline phosphatase (p<0.001) and alanine aminotransferase (p=0.040) levels were significantly higher in patients with malignant bile duct strictures than in those with bile duct stones.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [7, 10, 5, 3, 6, 2, 4, 1, 0, 9, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which company produces Keytruda?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \\u00e2\\u2030\\u00a550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \\u00e2\\u2030\\u00a51%), with disease progression on or after platinum-containing chemotherapy.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"INTERPRETATION: Pioglitazone did not delay the onset of mild cognitive impairment.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Cereblon (CRBN)  has been identified as the target for what type of drug?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 13, \"text\": \"Cereblon (CRBN) is a common primary target for IMiDs.\"}, {\"id\": 9, \"text\": \"Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM).\"}, {\"id\": 25, \"text\": \". Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs\\u00c2\\u00ae) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents.\"}, {\"id\": 28, \"text\": \"We have identified novel CRBN inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. \"}, {\"id\": 31, \"text\": \"Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(C\"}, {\"id\": 15, \"text\": \"ubiquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell \"}, {\"id\": 30, \"text\": \"cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh\"}, {\"id\": 17, \"text\": \" Cereblon (CRBN) is a common primary target for IMiDs.\"}, {\"id\": 22, \"text\": \"Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (CRBN) as a primary direct target of this drug b\"}, {\"id\": 19, \"text\": \" It additionally modulates the anti-myeloma effect of the immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation\"}, {\"id\": 4, \"text\": \"Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) .\"}, {\"id\": 7, \"text\": \"Cereblon is a well-known target of thalidomide and its derivatives.\"}, {\"id\": 24, \"text\": \"The molecular mechanism of action of IMiDs remained unclear for a long time until 2010 when the protein cereblon (CRBN) was identified as a primary direct target. IMiDs binds to CRBN and alters the substrate specificity of the CRBN E3 ubiquitin ligase complex, \"}, {\"id\": 18, \"text\": \"Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to le\"}, {\"id\": 29, \"text\": \"Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.\"}, {\"id\": 3, \"text\": \"Cereblon was identified as a direct target of thalidomide by Prof. H. Handa, and this pioneering work triggered active research on IMiDs (immunomodulatory drugs), which include thalidomide-derivatives, such as lenalidomide and pomalidomide.\"}, {\"id\": 26, \"text\": \"Cereblon (CRBN), a substrate receptor of the CRL4 ubiquitin ligase complex, is the primary target by which IMiDs mediate anticancer and teratogenic effects.\"}, {\"id\": 1, \"text\": \"The Cullin-RING ligase 4 E3 ubiquitin ligase component Cereblon (CRBN) is a well-established target for a class of small molecules termed immunomodulatory drugs (IMiDs).\"}, {\"id\": 27, \"text\": \"Thalidomide and its derivatives lenalidomide and\\u00c2\\u00a0pomalidomide, known as immunomodulatory drugs, (IMiDs)\\u00c2\\u00a0bind\\u00c2\\u00a0directly to cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase, resulting in the rapid ubiquitination and degradation of the substrate protein.\"}, {\"id\": 12, \"text\": \"Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.\"}, {\"id\": 14, \"text\": \"eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another \"}, {\"id\": 6, \"text\": \" Although the direct target of thalidomide was largely debated until recently, our groups discovered cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase as a primary target of thalidomide in 2010.\"}, {\"id\": 11, \"text\": \"Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was identified as primary target of thalidomide.\"}, {\"id\": 20, \"text\": \"Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.\"}, {\"id\": 8, \"text\": \"Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).\"}, {\"id\": 5, \"text\": \"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.\"}, {\"id\": 16, \"text\": \"d previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase c\"}, {\"id\": 0, \"text\": \"dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required \"}, {\"id\": 10, \"text\": \" We identified a thalidomide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity.\"}, {\"id\": 2, \"text\": \"CRBN has been identified as a direct target for immunomodulatory drugs (IMiD) and plays a significant role in anti-proliferation, pro-apoptotic effects, anti-angiogenic activities, immunomodulatory activities and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells.\"}, {\"id\": 23, \"text\": \"These results strongly suggest that increased BK channel activity is the pathological mechanism of intellectual disability in CRBN mutations.SIGNIFICANCE STATEMENTCereblon (CRBN), a well known target of the immunomodulatory drug thalidomide, was originally identified as a gene that causes human intellectual disability when mutated.\"}, {\"id\": 21, \"text\": \"Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [7, 28, 19, 25, 22, 24, 23, 5, 8, 12, 2, 27, 13, 26, 29, 11, 9, 21, 20, 3, 1, 10, 6, 17, 16, 0, 18, 31, 14, 4, 30, 15]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Does silencing of SRRM4 promote microexon inclusion?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Overexpressing SRRM4, known for regulating ME inclusion in mRNAs critical for neural differentiation, in human HEK293 cells resulted in the biogenesis of over 2000 novel ME-circRNAs, including ME-circEIF4G3, and changes in the abundance of many canonical circRNAs, including circSETDB2 and circLBRA. \"}, {\"id\": 0, \"text\": \"SRRM4 Expands the Repertoire of Circular RNAs by Regulating Microexon Inclusion.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which drugs are included in the AZD7442?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"BACKGROUND: Intramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs. \"}, {\"id\": 3, \"text\": \"AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). \"}, {\"id\": 0, \"text\": \"Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.\"}, {\"id\": 2, \"text\": \"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 2, 0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What were the first 2 PD-1 inhibitors approved by the FDA in 2014?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 5, \"text\": \"s paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.\"}, {\"id\": 9, \"text\": \"The US Food and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation.\"}, {\"id\": 2, \"text\": \"The first monoclonal antibodies against the immune checkpoint programmed death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use\"}, {\"id\": 10, \"text\": \"The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan.\"}, {\"id\": 3, \"text\": \" Pembrolizumab is one of the first immune checkpoint inhibitors approved by the FDA to treat NSCLC and is currently the only immunotherapy drug approved for first-line treatment of NSCLC in immune checkpoint inhibitors.\"}, {\"id\": 6, \"text\": \" A PD-1 antibody, nivolumab, was the first of these agents to be approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, as a new cancer drug for melanoma, in July 2014.\"}, {\"id\": 4, \"text\": \"2 different programmed cell death protein 1 (PD-1) inhibitors, Nivolumab and Pembrolizumab.\"}, {\"id\": 7, \"text\": \"other tumors. In 2014, nivolumab and pembrolizumab, two checkpoint inhibitors binding to PD-1, were approved for the treatment of metast\"}, {\"id\": 1, \"text\": \"e programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma.\"}, {\"id\": 11, \"text\": \"Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.\"}, {\"id\": 12, \"text\": \"ministration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully h\"}, {\"id\": 0, \"text\": \"The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan. \"}, {\"id\": 8, \"text\": \"Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 2, 1, 0, 11, 8, 9, 10, 7, 3, 6, 5, 12]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the difference between dermatillomania and skin picking disorder?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What causes Japanese Spotted Fever?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (JSF; a spotted fever group rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia.\"}, {\"id\": 2, \"text\": \"Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (JSF) and can transmit to humans via infected ticks. \"}, {\"id\": 1, \"text\": \"Non-pathogenic Rickettsia species LON strains closely related to an agent of Japanese spotted fever (JSF), R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the difference between PD-1 and PD-L1?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 9, \"text\": \"PD-1 has two ligands: PD-1 ligand 1 (PD-L1), which is expressed broadly on hematopoietic and parenchymal cells, including pancreatic islet cells; and PD-L2, which is restricted to macrophages and dendritic cells.\"}, {\"id\": 13, \"text\": \"Engagement of programmed death-1 (PD-1) with its two ligands [programmed death ligand-1 (PD-L1) and PD-L2] has been associated with the suppression of tumor-reactive T cells; however, the underlying mechanism for this T-cell dysfunction is not clear.\"}, {\"id\": 12, \"text\": \"Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies.\"}, {\"id\": 15, \"text\": \"PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages.\"}, {\"id\": 3, \"text\": \"PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery.\"}, {\"id\": 0, \"text\": \"osuppression. Programmed death-1 (PD1) and its ligand programmed death ligand-1 (PD-L1) exert inhibitory function by regulating the balance among T cell activation, tolerance, and im\"}, {\"id\": 14, \"text\": \"Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors.\"}, {\"id\": 10, \"text\": \"PD-1 interacts with two ligands, PD-L1 and PD-L2.\"}, {\"id\": 7, \"text\": \"Finally, we could demonstrate that PD-L1 and PD-L2 competed for PD-1 binding and conversely, an antagonist PD-1 mAb blocked both PD-L1 and PD-L2 binding to PD-1 and strongly enhanced T-cell proliferation.\"}, {\"id\": 4, \"text\": \"Programmed death-1 (PD-1) is an immune checkpoint that is able to inhibit the immune system by binding to its ligand programmed death-ligand 1 (PD-L1).\"}, {\"id\": 1, \"text\": \" Inhibitors of programmed cell death-1 (PD-1) and its ligand (PD-L1) have been increasingly used in head and neck cancer therapy and reported to improve the outcomes with an acceptable safety profile.\"}, {\"id\": 8, \"text\": \"BACKGROUND: Monoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are effective therapies in patients with non-small cell lung can\"}, {\"id\": 11, \"text\": \"Importance: Immune checkpoint inhibitors of programmed cell death 1 (PD-1) and its ligand (PD-L1) have led to a paradigm shift in cance\"}, {\"id\": 6, \"text\": \"To compare the real-world safety profile of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors between younger and older patients\"}, {\"id\": 2, \"text\": \"ast cancer. Programmed death-1 (PD-1) and its ligand, programmed death-ligand 1\\u00c2\\u00a0(PD-L1), seem to have prognostic and predictive values in a variety of cancers, including female br\"}, {\"id\": 5, \"text\": \"PD-1 has two ligands PD-L1 and PD-L2.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [6, 14, 1, 13, 10, 12, 9, 8, 3, 15, 4, 7, 2, 11, 0, 5]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What would be the benefits of using a virtual digital twin in nutrition?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"We herein discuss how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a \\\"virtual digital twin,\\\" which could serve to guide nutrition in a personalized manner. Such a model may revolutionize the management of obesity and its comorbidities, and provide a pillar for healthy aging.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is levosimendan effective for amyotrophic lateral sclerosis?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"INTERPRETATION: Levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo.\"}, {\"id\": 0, \"text\": \"CONCLUSIONS: Levosimendan did not achieve the primary endpoint of improving sitting SVC in ALS. Headache and increased heart rate were increased on levosimendan, although it was otherwise well tolerated. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the clinical symptoms of an ornithine transcarbamylase deficiency?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"extreme irritability (100 percent), episodic vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures\"}, {\"id\": 0, \"text\": \"Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia\"}, {\"id\": 4, \"text\": \"Ornithine transcarbamylase deficiency causes vomiting, lethargy, hyperventilation, and even death, mainly in the neonatal period.\"}, {\"id\": 1, \"text\": \"Ornithine transcarbamylase deficiency (OTC-D) is an X-linked metabolic disease and the most common urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual\"}, {\"id\": 3, \"text\": \"X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 1, 0, 2, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'How does SRSF11 contribute to metastasis potential of colorectal cancer?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"SRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA. Our findings point to SRSF11-regulated HSPA12A splicing as a novel relationship between SRSF11-regulated splicing and CRC metastasis and suggest a PAK5/SRSF11/HSPA12A axis as a potential therapeutic target and prognostic biomarker in CRC.\"}, {\"id\": 0, \"text\": \"Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Olokizumab is tested for which disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX).\"}, {\"id\": 0, \"text\": \"CONCLUSIONS: Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. \"}, {\"id\": 4, \"text\": \"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.\"}, {\"id\": 5, \"text\": \"CONCLUSIONS: In patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. \"}, {\"id\": 3, \"text\": \"Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.\"}, {\"id\": 1, \"text\": \"BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 2, 0, 3, 1, 5]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Please summarize the function of Trophinin-associated protein (TROAP)' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 19, \"text\": \"Altogether, our results show that TROAP is a novel crucial regulator of HCC progression and is a potential therapeutic biomarker for HCC patients.\"}, {\"id\": 2, \"text\": \"on subtype. Trophinin-associated protein (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in microtubule\"}, {\"id\": 21, \"text\": \"Trophinin-associated protein (TROAP) was a protein first identified to mediate the process of embryo transplantation and later found to be involved in microtubule regulation.\"}, {\"id\": 13, \"text\": \"TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.\"}, {\"id\": 14, \"text\": \"BACKGROUND: Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior o\"}, {\"id\": 22, \"text\": \"ophinin-associated protein expression is an independent prognostic biomarker in lung adenocarcinoma.\"}, {\"id\": 3, \"text\": \"Trophinin-associated protein (TROAP) is a cytoplasmic protein required for microtubular cytoskeleton regulation and spindle assembly, and its expression plays a critical role in the initiation and progression of various types of cancer.\"}, {\"id\": 20, \"text\": \"Purpose: Trophinin-associated protein (TROAP) is a cytoplasmic protein that plays a significant role in the processes of embryo transplantation and microtubule regulation.\"}, {\"id\": 7, \"text\": \"BACKGROUND: Trophinin-associated protein (TROAP) is a cytoplasmic protein that functions as an adhesion molecule in processes such as embryo implantation, spindle formation, and cancer.OBJECTIVE: To evaluate the relationship of TROAP expression in hepatocellular carcinoma (HCC) tissue with clinicopathologic parameters and survival time in liver cancer patients based on an analysis of The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data.METHODS: RNA-sequencing (RNA-Seq) expression data and clinical information were down\"}, {\"id\": 6, \"text\": \"Trophinin-associated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors.\"}, {\"id\": 26, \"text\": \"The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma.\"}, {\"id\": 15, \"text\": \"Clear cell renal cell carcinoma (ccRCC) is a subtype of renal cell cancer with the highest mortality, infiltration, and metastasis rate, threatening human health. Despite oncogenic role of TROAP in various cancers, its function in ccRCC remains to be unraveled.\"}, {\"id\": 24, \"text\": \"ctopic expression of trophinin-associated protein (TROAP) dramatically drove HCC cell growth assessed by foci formation in monolayer culture, colony f\"}, {\"id\": 23, \"text\": \"BACKGROUND: Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of vari\"}, {\"id\": 28, \"text\": \"Downregulated Trophinin-Associated Protein Plays a Critical Role in Human Hepatocellular Carcinoma Through Upregulation of Tumor Cell Growth and Migration.\"}, {\"id\": 16, \"text\": \"TROAP depletion significantly enhanced the proliferation and colony formation abilities, whereas TROAP overexpression had an inhibitory effect on the growth of HCC cells.\"}, {\"id\": 29, \"text\": \"n (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in \"}, {\"id\": 25, \"text\": \"Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC.\"}, {\"id\": 27, \"text\": \"Trophinin associated protein (TROAP) is a cytoplasmic protein required for spindle assembly and cell invasion; however, its biological function in cancer remains to be elucidated\"}, {\"id\": 4, \"text\": \"AIMS: Experimental evidence demonstrated a crucial role of TROAP (Trophinin-associated protein) in regulating the cell proliferation of multiple tumors, while TROAP expression and function were largely unknown in glioma.\"}, {\"id\": 30, \"text\": \"n (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in microtubule regulation. However, limited informati\"}, {\"id\": 5, \"text\": \"Trophinin and tastin, a novel cell adhesion molecule complex with potential involvement in embryo implantation.\"}, {\"id\": 0, \"text\": \". Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC. This discovery will further our understanding of \"}, {\"id\": 18, \"text\": \"ROAP regulates cell cycle and promotes tumor progression through Wnt/\\u00ce\\u00b2-Catenin signaling pathway in glioma cells.\"}, {\"id\": 10, \"text\": \"ciated protein (TROAP) is a cytoplasmic protein that functions as an adhesion molecule in processes such as embryo implantation, spindle formation, and cancer.OBJECTIVE: To evaluate th\"}, {\"id\": 17, \"text\": \"BACKGROUND: Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of various cancers\"}, {\"id\": 11, \"text\": \"sociated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors. We performed this study to assess the biolo\"}, {\"id\": 1, \"text\": \": Our results suggested that TROAP is an independent prognostic biomarker of poor survival in LAC\"}, {\"id\": 12, \"text\": \"Trophinin associated protein (TROAP) is a cytoplasmic protein required for spindle assembly and cell invasion; however, its biological function in cancer remains to be elucidated.\"}, {\"id\": 31, \"text\": \"Conclusions: Elevated TROAP expression predicted a poor prognosis, and TROAP may serve as a potential biomarker for application in oncotherapy.\"}, {\"id\": 8, \"text\": \"Trophinin associated protein (TROAP) is essential for centrosome integrity and proper bipolar organisation of spindle assembly during mitosis and plays an essential role in proliferation.\"}, {\"id\": 9, \"text\": \"l role of TROAP (Trophinin-associated protein) in regulating the cell proliferation of multiple tumors, while TROAP expression and function were largely unknown in glioma. We aimed to investigate the oncogenic role of T\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [18, 27, 21, 20, 2, 8, 23, 25, 28, 16, 3, 12, 7, 13, 31, 26, 19, 5, 6, 14, 11, 24, 0, 29, 17, 30, 9, 10, 4, 15, 22, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'How does SRSF11 promote metastasis of colon cancer?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Alternative splicing of HSPA12A pre-RNA by SRSF11\"}, {\"id\": 1, \"text\": \"SRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA. Our findings point to SRSF11-regulated HSPA12A splicing as a novel relationship between SRSF11-regulated splicing and CRC metastasis and suggest a PAK5/SRSF11/HSPA12A axis as a potential therapeutic target and prognostic biomarker in CRC.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What disease can be treated with Lenacapavir?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 5, \"text\": \"Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.\"}, {\"id\": 1, \"text\": \"The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair HIV-1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores. \"}, {\"id\": 2, \"text\": \"PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history.\"}, {\"id\": 3, \"text\": \"Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. \"}, {\"id\": 7, \"text\": \"In heavily treatment-experienced persons with multidrug-resistant HIV-1 and in treatment-naive persons with HIV-1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated.SUMMARY: Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.\"}, {\"id\": 4, \"text\": \"Lenacapavir (Sunlenca\\u00c2\\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\\u00c2\\u00a01 (HIV-1) being developed by Gilead Sciences Inc. \"}, {\"id\": 6, \"text\": \"In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.\"}, {\"id\": 0, \"text\": \"Lenacapavir: a first-in-class HIV-1 capsid inhibitor.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 3, 1, 4, 6, 0, 2, 7]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is Iron deficiency anemia a common complication of chronic kidney disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 20, \"text\": \"e treatment of anemia in chronic kidney disease.\"}, {\"id\": 7, \"text\": \"Anemia resulting from iron and erythropoietin deficiencies is a common complication of advanced chronic kidney disease (CKD).\"}, {\"id\": 76, \"text\": \"he current management of patients with anemia in CKD is controversial, with recent c\"}, {\"id\": 14, \"text\": \"safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.\"}, {\"id\": 47, \"text\": \"The diagnosis of iron deficiency anemia in patients with CKD is complicated due to the relatively low predictive ability of routine serum iron markers (e.g., ferritin and transferrin saturation) and more invasive measurements such as bone marrow iron stores.\"}, {\"id\": 33, \"text\": \"nemia in diabetic kidney disease - underappreciated but still clinically relevant proble\"}, {\"id\": 13, \"text\": \"Iron deficiency anemia is a common complication in end-stage renal disease (ESRD) and impairs the therapeutic efficacy of recombinant erythropoietin.\"}, {\"id\": 42, \"text\": \"However, the diagnosis of iron-deficiency anemia in CKD patients is complicated by the relatively poor predictive ability of easily obtained routine serum iron indices (eg, ferritin and transferrin saturation) and more invasive gold standard measures of iron deficiency (eg, bone marrow iron stores) or erythropoietic response to supplemental iron.\"}, {\"id\": 19, \"text\": \"BACKGROUND: Iron deficiency anemia and serum phosphate levels > 4.0mg/dL are relatively common in chronic kidney disease stages 3 to 5 and are associated with higher risks of progressive loss of kidney function, cardiovascular events, and mortality.STUDY DESIGN: Double-blind, placebo-controlled, randomized trial.SETTING & PARTICIPANTS: 149 patients with estimated glomerular filtration rates < 60 mL/min/1.73 m(2), iron deficiency anemia (hemoglobin, 9.0-12.0 g/dL; transferrin saturation [TSAT]\\u00e2\\u2030\\u00a4 30%, serum ferritin \\u00e2\\u2030\\u00a4 300 ng/\"}, {\"id\": 5, \"text\": \"nemia in chronic kidney disease\"}, {\"id\": 80, \"text\": \"he prevalence of iron deficiency and its contribution to the anemia of end stage renal disease has been extensively studied, but much less is known about the role of iron deficiency in the pathogenesis of the anemia of chronic kidney disease in predialysis patients.\"}, {\"id\": 26, \"text\": \"Urology and nephrology update: anemia of chronic kidney disease.\"}, {\"id\": 23, \"text\": \" Deciding on the appropriate treatment for anemia associated with CKD\"}, {\"id\": 16, \"text\": \"Anemia in CKD is associated with an increased risk of morbidity and mortality.\"}, {\"id\": 60, \"text\": \"Treatment with iron preparations remains one of the main directions in the treatment of anemia in patients with chronic kidney disease.\"}, {\"id\": 21, \"text\": \"Iron deficiency anemia is a common complication of chronic kidney disease (CKD).\"}, {\"id\": 75, \"text\": \"ythropoietin resistance in the treatment of the anemia of chronic renal failure\"}, {\"id\": 31, \"text\": \"Anemia is a common feature of CKD associated with poor outcomes.\"}, {\"id\": 46, \"text\": \" Ferumoxytol for Anemia of CKD Trial \"}, {\"id\": 2, \"text\": \" diabetic nephropathy is a leading cause of CKD. One of the most common complications of CKD is anemia, the frequency and severity of which increase a\"}, {\"id\": 43, \"text\": \"Anemia is an adverse outcome and common complication in chronic kidney disease patient\"}, {\"id\": 55, \"text\": \"Severe anemia and iron deficiency are common complications in chronic kidney disease.\"}, {\"id\": 12, \"text\": \"nemia in children with chronic kidney disease (CKD) is common secondary to inadequate erythropoietin production\"}, {\"id\": 34, \"text\": \"nemia in renal disease: diagnosis and manageme\"}, {\"id\": 35, \"text\": \"nemia in chronic kidney disease\"}, {\"id\": 56, \"text\": \"Anemia in children with chronic kidney disease\"}, {\"id\": 49, \"text\": \"o anemia. The other cause of anemia is deficiency of iron. Iron deficiency anemia is common in people with CKD and its importance in supporting erythr\"}, {\"id\": 0, \"text\": \"esistance to erythropoietin therapy is a common complication of the modern management of anemia in chronic kidney disease\"}, {\"id\": 73, \"text\": \"BACKGROUND: Iron deficiency anemia (IDA) is a common manifestation of chronic kidney disease (CKD), affecting most patients on hemodialysis and imposing a substantial clin\"}, {\"id\": 28, \"text\": \"nemia is a common complication in chronic kidney disease (CKD), and is associated with a reduced quality of life,\"}, {\"id\": 10, \"text\": \"f Anemia in Chronic Kidney Disease: Beyond Erythropoietin\"}, {\"id\": 29, \"text\": \"Anemia and its predictors among adult non-dialysis chronic kidney disease patients in Southern Ethiopia: a cross-sectional study.\"}, {\"id\": 62, \"text\": \"Iron Deficiency Anemia in Chronic Kidney Disease.\"}, {\"id\": 38, \"text\": \"echanisms of anemia in CKD\"}, {\"id\": 67, \"text\": \"Anemia is a common complication of chronic kidney disease (CKD) in predialysis stage.\"}, {\"id\": 61, \"text\": \" anemia and reduction of serum phosphate in patients with CKD\"}, {\"id\": 4, \"text\": \"Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency.\"}, {\"id\": 50, \"text\": \" iron deficiency in patients with chronic kidney disease (CKD), either with or without anaemia. \"}, {\"id\": 72, \"text\": \"Anemia is a frequent complication during the later stages of chronic kidney disease.\"}, {\"id\": 41, \"text\": \"nemia of Inflammation with An Emphasis on Chronic Kidney Disease\"}, {\"id\": 27, \"text\": \"Among CKD patients, absolute iron deficiency is defined when the transferrin saturation (TSAT) is \\u00e2\\u2030\\u00a420% and the serum ferritin concentration is \\u00e2\\u2030\\u00a4100 ng/mL among predialysis and peritoneal dialysis patients or \\u00e2\\u2030\\u00a4200 ng/mL among hemodialysis patients.\"}, {\"id\": 74, \"text\": \" retrospective study was conducted over seven years and it aimed to find out various causes of anemia among patients with chronic kidney disease (CKD).\"}, {\"id\": 77, \"text\": \"Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal diseas\"}, {\"id\": 79, \"text\": \"nemia is a common complication of chronic kidney disease\"}, {\"id\": 78, \"text\": \"Anemia is associated with chronic kidney disease (CKD) at all stages, and it is nearly universal among patients with stage 5 CKD\"}, {\"id\": 32, \"text\": \"Anemia is a common complication of chronic kidney disease.\"}, {\"id\": 30, \"text\": \" development and treat complications including anemia. Anemia is one of the common complication of chronic kidney disease (CKD), which is a significan\"}, {\"id\": 58, \"text\": \" Limited data suggest that iron deficiency is common in patients with chronic kidney disease with anemia; this lack of iron can hinder the effectiveness of erythropoiesis.\"}, {\"id\": 40, \"text\": \"Iron deficiency, both functional and absolute, is common in patients with chronic kidney disease (CKD), especially those requiring dialysis.\"}, {\"id\": 15, \"text\": \"Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease.\"}, {\"id\": 39, \"text\": \"nemia is a common complication of chronic kidney disease (CKD), and its prevalence has shown a tendency to increase in many countries.\"}, {\"id\": 17, \"text\": \"Iron deficiency anemia is a common occurrence in patients with chronic kidney disease and many patients do not respond well to supplementation with oral iron.\"}, {\"id\": 51, \"text\": \"Chronic kidney disease (CKD) is a widespread health problem in the world and anemia is a common complication\"}, {\"id\": 66, \"text\": \"spectrum of anemia in non-dialysis-dependent chronic kidney disease\"}, {\"id\": 70, \"text\": \"Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.\"}, {\"id\": 1, \"text\": \"Intravenous iron therapy is increasingly being used worldwide to treat anemia in chronic kidney disease and more recently iron deficiency in heart failure.\"}, {\"id\": 18, \"text\": \"This work presents an update on the management of iron deficiency in patients with chronic renal failure (CRF), either with or without anaemia.\"}, {\"id\": 52, \"text\": \"options for the anemia of chronic kidney disease.\"}, {\"id\": 71, \"text\": \" chronic kidney disease, anemia and malnutrition coupled with inflammation as malnutrition-inflammation complex syndrom are common and considered as morbidity-mortality factors\"}, {\"id\": 9, \"text\": \"Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency\"}, {\"id\": 24, \"text\": \"Anemia in ESRD and Earlier Stages of CKD\"}, {\"id\": 44, \"text\": \"Anemia is a common and clinically important consequence of chronic kidney disease (CKD).\"}, {\"id\": 68, \"text\": \"nemia is common and associated with adverse outcomes in children with chronic kidney disease (CKD\"}, {\"id\": 8, \"text\": \"BACKGROUND: Iron deficiency anemia is a common complication in patients with chronic kidney di\"}, {\"id\": 57, \"text\": \"nemia in Chronic Kidney Disease: \"}, {\"id\": 54, \"text\": \"Iron deficiency anemia (IDA) is a frequent complication of chronic kidney disease (CKD) and is associated with adverse outcomes in these patients.\"}, {\"id\": 37, \"text\": \"Prevalence of malnutrition and absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease and hemodialysis Algerian patients]\"}, {\"id\": 45, \"text\": \"Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients.\"}, {\"id\": 11, \"text\": \"ron replacement therapy in the management of anaemia in non-dialysis chronic renal failure patients:\"}, {\"id\": 64, \"text\": \"Anemia is a common complication in patients with chronic kidney disease (CKD), mainly due to inadequate renal production of erythropoietin. In hemodia\"}, {\"id\": 36, \"text\": \"Iron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia.\"}, {\"id\": 63, \"text\": \"Anemia is a frequent complication of kidney disease.\"}, {\"id\": 25, \"text\": \"Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin.\"}, {\"id\": 3, \"text\": \"Anemia in chronic kidney disease is common and iron deficiency is an important cause.\"}, {\"id\": 6, \"text\": \"Anemia is a frequent complication in chronic kidney disease (CKD), and it is often accompanied by various clinical symptoms. The primary cause of anem\"}, {\"id\": 69, \"text\": \"Severe anemia and iron deficiency are common complications in chronic kidney disease. The cause of renal anemia is multifactorial and includes decreas\"}, {\"id\": 65, \"text\": \"Here, we examine recent insights into the molecular mechanisms underlying anemia of CKD\"}, {\"id\": 59, \"text\": \"Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especiall\"}, {\"id\": 48, \"text\": \"Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin.\"}, {\"id\": 22, \"text\": \" Treatment of Anemia in Patients with Chronic Kidney Disease\"}, {\"id\": 53, \"text\": \"nemia is a frequent comorbidity of chronic kidney disease (CKD) \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 50, 40, 60, 18, 11, 21, 62, 73, 67, 44, 27, 8, 54, 13, 16, 19, 7, 36, 17, 42, 48, 25, 58, 63, 32, 55, 59, 9, 2, 77, 69, 64, 49, 15, 30, 47, 6, 4, 72, 3, 5, 68, 20, 80, 34, 45, 70, 23, 35, 24, 46, 61, 51, 33, 56, 12, 38, 31, 76, 65, 41, 22, 39, 75, 0, 66, 74, 14, 52, 79, 26, 78, 57, 28, 29, 43, 37, 71, 10, 53]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can modulation of KCNQ1 splicing prevent arrhythmias?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Amiloride regulates IKs and APs with transmural differences and reduces arrhythmogenicity through the modulation of KCNQ1 splicing. We suggested that the modulation of KCNQ1 splicing may help prevent arrhythmia.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is Catamenial pneumothorax?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"BACKGROUND: Catamenial pneumothorax (CP) is defined as a recurrent, spontaneous pneumothorax occurring within a day before or 72\\u00c2\\u00a0h after the onset of menstruation. \"}, {\"id\": 2, \"text\": \"Thoracic endometriosis is a rare extrapelvic location of endometriosis and the leading cause of catamenial pneumothorax. \"}, {\"id\": 1, \"text\": \"Thoracic endometriosis syndrome (TES) is a rare disorder characterized by the presence of ectopic endometrial tissue in the chest cavity. The typical clinical manifestation is a spontaneous pneumothorax, which usually presents with chest pain, dyspnea, and/or cough. \"}, {\"id\": 7, \"text\": \"OBJECTIVE: This review aimed to categorize thoracic endometriosis syndrome (TES) according to whether the presenting symptoms were catamenial and to evaluate whether such a categorization enables a better management strategy.\"}, {\"id\": 0, \"text\": \"Catamenial pneumothorax: a rare manifestation of endometriosis.\"}, {\"id\": 8, \"text\": \"OBJECTIVE: The menstrual-related catamenial pneumothorax (CP) can be the first expression of thoracic endometriosis syndrome (TES), which is the presence of endometriotic lesions in the lungs and pleura, and pelvic endometriosis (PE).\"}, {\"id\": 5, \"text\": \"Catamenial Pneumothorax as the First Expression of Thoracic Endometriosis Syndrome and Pelvic Endometriosis.\"}, {\"id\": 4, \"text\": \"Catamenial pneumothorax is one of the most frequent manifestation in terms of a thoracic endometriosis syndrome (TES).\"}, {\"id\": 6, \"text\": \"OBJECTIVES: Catamenial pneumothorax CP is a rare form of spontaneous pneumothorax in females forming part of thoracic endometriosis syndrome. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 5, 8, 0, 2, 3, 6, 7, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Please summarize haptenization.' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Drug presentation via antigen-presenting cells to T cells can either involve the classical pathway of haptenization of endogenous proteins or be directly mediated via noncovalent binding to immune receptors (MHC molecules or T cell receptors), t\"}, {\"id\": 0, \"text\": \"Her particular hepatic metabolism further increased the drugs' concentration, favoring the haptenization of liver proteins, eventually leading to the development of an autoimmune hepatitis.\"}, {\"id\": 2, \"text\": \"In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of prot\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is trichotillomania encountered with equali frequency in males and females?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"The disease affects mainly female patients, who often deny the habit, and it usually presents with a bizarre pattern nonscarring patchy alopecia with short hair and a negative pull test. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the triad of the Eagle-Barrett Syndrome?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Prune Belly syndrome (PBS) or Eagle-Barrett syndrome is an anatomo-radiological syndrome consisting of a complex and rare malformation characterized by the following triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism.\"}, {\"id\": 1, \"text\": \"Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.\"}, {\"id\": 0, \"text\": \"BACKGROUND: Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome (EGBRS), is a rare congenital disease characterized by deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism.\"}, {\"id\": 3, \"text\": \"Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome, is a rare congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0, 2, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What cells proliferate in Mantle Cell Lymphoma' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males. \"}, {\"id\": 9, \"text\": \"Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma with a generally aggressive and heterogeneous clinical course. Chemokines are one of the complex components in the tumor microenvironment (TME), and they play a vital role in tumor progression and metastasis.\"}, {\"id\": 5, \"text\": \"Mantle cell lymphoma is an aggressive, non-curable B-cell lymphoma, characterized by the translocation t(11;14)(q13;q32) involving CCND1 and a high number of additional genetic alterations.\"}, {\"id\": 3, \"text\": \"BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and genetically by t(11;14)(q13;q32) with overexpression of the cyclin D1 (bcl-1) gene\"}, {\"id\": 8, \"text\": \"Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenstr\\u00c3\\u00b6m macroglobulinemia (WM)\"}, {\"id\": 0, \"text\": \"Mantle cell lymphoma (MCL) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy,\"}, {\"id\": 4, \"text\": \"BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and g\"}, {\"id\": 7, \"text\": \"BACKGROUND: Mantle zone lymphoma (MZL) is a B-cell proliferation regarded as the follicular variant of intermediate lymphocytic lym\"}, {\"id\": 2, \"text\": \"Mantle cell lymphoma (MCL) is a B cell non-Hodgkin's lymphoma, characterized by a poor response to therapy and short survival.\"}, {\"id\": 6, \"text\": \"Mantle cell lymphoma is a B cell lymphoproliferative disorder cytogenetically characterized by the t(11;14)(q13;q32) which at molecular level involves the Bcl-1/PRAD-1 gene.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 8, 1, 5, 2, 6, 7, 4, 3, 9]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the estimated cost reduction when using telegenetics?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the target of BI 1015550?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 5, \"text\": \"BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B.\"}, {\"id\": 1, \"text\": \"BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.\"}, {\"id\": 2, \"text\": \"Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.\"}, {\"id\": 4, \"text\": \"Introduction: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. \"}, {\"id\": 3, \"text\": \"METHODS: In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis.\"}, {\"id\": 0, \"text\": \"In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 2, 4, 1, 5, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Please summarize the difference between REMS and RMPs' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Both REMS and RMPs provide positive guidance for identification, monitoring, and minimization of risk to patient safety. Currently, neither agency provides specific guidance on how risk should be related to benefit either qualitatively or quantitatively.\"}, {\"id\": 0, \"text\": \"REMS requirements include medication guides, communication plans, elements to ensure safe use, implementation systems, and specified assessment intervals. RMP requirements are increased pharmacovigilance and risk minimization activities.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Microexon alternative splicing of small GTPase regulators: Implication in central nervous system diseases.\"}, {\"id\": 0, \"text\": \"We further discuss the emerging evidence for dysregulation of the Rho GTPase pathway in CNS diseases and the consequences contributed by the mis-splicing of microexons. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Beremagene Geperpavec is tested for which disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. \"}, {\"id\": 0, \"text\": \"These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Hairpatches is a single gene mutation associated with what disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse.\"}, {\"id\": 3, \"text\": \"\\\"Hairpatches\\\" (Hpt) is a naturally occurring, autosomal semi-dominant mouse mutation. Hpt/Hpt homozygotes die in utero, while Hpt/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia. \"}, {\"id\": 2, \"text\": \"Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.\"}, {\"id\": 0, \"text\": \"Retrotransposon insertion in the T-cell acute lymphocytic leukemia 1 (Tal1) gene is associated with severe renal disease and patchy alopecia in Hairpatches (Hpt) mice.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 2, 0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"RNA interference-mediated knockdown experiments identified two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Differential microexon splicing was shown to be due, at least in part, to altered expression of RBFOX2 and PTBP1 in CRC tissue compared to matched normal tissue. \"}, {\"id\": 1, \"text\": \"Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.\"}, {\"id\": 3, \"text\": \"Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.\"}, {\"id\": 2, \"text\": \"Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 2, 0, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which gene is implicated in Canavan disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Canavan disease (CD) is a devastating neurological disease that lacks effective therapy. Because CD is caused by mutations of the aspartoacylase (ASPA) gene, we introduced the wild-type (WT) ASPA gene into patient iPSCs through lentiviral transduction or CRISPR/Cas9-mediated gene editing. \"}, {\"id\": 0, \"text\": \"Canavan disease (CD) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA). \"}, {\"id\": 1, \"text\": \"The compound heterozygous variants of the ASPA gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family.\"}, {\"id\": 3, \"text\": \"Genetic analysis revealed novel mutations in the aspartoacylase or ASPA gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.\"}, {\"id\": 4, \"text\": \"Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of ASPA Gene.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 3, 0, 2, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is prosopagnosia also known as lack of auditory recognition?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 16, \"text\": \"Developmental prosopagnosia (DP) is a condition characterised by lifelong face recognition difficulties.\"}, {\"id\": 7, \"text\": \"Prosopagnosia (PA) or face blindness is characterized by a deficiency in identifying familiar faces.\"}, {\"id\": 14, \"text\": \"The patient is unable to recognize faces or cars, consistent with his prosopagnosia and object agnosia, respectively.\"}, {\"id\": 12, \"text\": \"In recent years, prosopagnosia is defined as the \\\"loss of ability to recognize the well-acquainted persons like the family members by their physiognomy.\\\"\"}, {\"id\": 4, \"text\": \"Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquire\"}, {\"id\": 17, \"text\": \"The apparent selectivity of agnosia for faces is termed prosopagnosia or face blindness.\"}, {\"id\": 3, \"text\": \"BACKGROUND: Developmental prosopagnosia is a disorder of face recognition that is believed to reflect impairments of visual mechanisms. However, voice recognition has rarely been evaluated in developmental pro\"}, {\"id\": 0, \"text\": \"These results indicate that, in some subjects with developmental prosopagnosia, the face recognition deficit is not an isolated impairment but is associated with deficits in other domains, such as auditory perception.\"}, {\"id\": 10, \"text\": \"Prosopagnosia is a selective visual agnosia characterized by the inability to recognize the identity of faces.\"}, {\"id\": 5, \"text\": \"Prosopagnosia is a rare neurological sign, characterized by disturbance of recognition of faces.\"}, {\"id\": 15, \"text\": \"Since face recognition is the most powerful source of information for identifying familiar people, patients showing a multimodal defect in people recognition have been sometimes considered as affected by \\\"prosopagnosia\\\"-namely, by a form of visual agnosia, specifically affecting face recognition.\"}, {\"id\": 9, \"text\": \"Prosopagnosia is a selective impairment of the visual learning and recognition of faces.\"}, {\"id\": 13, \"text\": \"INTRODUCTION: The prosopagnosia has generally been defined as an incapacity to recognize familiar faces, or faces previously known, due to certain lesions to certain areas of the ce\"}, {\"id\": 1, \"text\": \"Prosopagnosia is a visual agnosia characterized by an inability to recognize previously known human faces and to learn new faces\"}, {\"id\": 2, \"text\": \"Prosopagnosia is a type of visual agnosia with inability to identify faces, usually secondary to brain lesion in associative cortex areas, but there is also a congenital form known as developmental prosopagnosia.\"}, {\"id\": 11, \"text\": \"Visual object agnosia refers to the inability to recognize objects and prosopagnosia to the failure to recognize faces that are well familiar to the patient, when stimuli are visually perceived.\"}, {\"id\": 6, \"text\": \" This rarely studied form of prosopagnosia ensures that deficits are limited to face recognition.\"}, {\"id\": 8, \"text\": \"Anecdotally, it has been reported that individuals with acquired prosopagnosia compensate for their inability to recognize faces by using other person identity cues such as hair, gait or the voice.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 2, 0, 7, 17, 12, 14, 8, 11, 15, 10, 5, 13, 16, 3, 9, 6, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is telegenetics?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Telegenetics involves the use of technology (generally video conferencing) to remotely provide genetic services. A telegenetics platform is critical for those with limitations or vulnerabilities compromising their ability to attend clinic in-person, including individuals in rural areas.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the mechanism of action of Mitapivat?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.\"}, {\"id\": 4, \"text\": \"Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \\u00ce\\u00b1-thalassaemia or \\u00ce\\u00b2-thalassaemia: an open-label, multicentre, phase 2 study.\"}, {\"id\": 2, \"text\": \"In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. \"}, {\"id\": 1, \"text\": \"We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \\u00ce\\u00b1-thalassaemia or NTD \\u00ce\\u00b2-thalassaemia.\"}, {\"id\": 0, \"text\": \"BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 2, 4, 1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Do cells undergoing necroptosis show disruption of their cell membranes?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome.\"}, {\"id\": 15, \"text\": \" Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\"}, {\"id\": 3, \"text\": \"Necroptosis is a programmed cell death pathway triggered by activation of receptor interacting protein kinase 3 (RIPK3), which phosphorylates and activates the mixed lineage kinase-like domain pseudokinase, MLKL, to rupture or permeabilize the plasma membrane.\"}, {\"id\": 9, \"text\": \"Here, we show that, during necroptosis, MLKL-dependent calcium (Ca2+) influx and phosphatidylserine (PS) exposure on the outer leaflet of the plasma membrane preceded loss of PM integrity.\"}, {\"id\": 10, \"text\": \"Membrane Disruption by Very Long Chain Fatty Acids during Necroptosis.\"}, {\"id\": 8, \"text\": \" non-inflammatory process while necrosis triggers inflammation. Recent studies on necroptosis and pyroptosis, two types of programmed necrosis, revealed that plasma membrane rupture is mediated by MLKL channels during necroptosis but depen\"}, {\"id\": 19, \"text\": \"uring necroptosis. We show that MLKL and phosphoMLKL, key for membrane permeabilization, are exclusively acylated during necroptosis. Reducing the lev\"}, {\"id\": 0, \"text\": \"Necroptosis induction leads to cell membrane disruption, inflammation and vascularization.\"}, {\"id\": 7, \"text\": \"Taken together, these results confirm the active role of VLCFAs during necroptosis and point to multiple potential mechanisms of membrane disruption including direct permeabilization via bilayer disruption and permeabilization by targeting of proteins to cellular membranes by fatty acylation.\"}, {\"id\": 1, \"text\": \"anslocates to and disrupts the plasma membrane, thereby causing necroptotic cell lysis. Herein, we show that activation of necroptosis in mouse dermal\"}, {\"id\": 12, \"text\": \"Necroptosis is a highly inflammatory form of programmed cell death that results from MLKL-mediated disruption of the cell membrane.\"}, {\"id\": 16, \"text\": \"Necroptosis, a form of programmed cell death, is characterized by the loss of membrane integrity and release of intracellular contents, the execution of which depends on the membrane-disrupting activity of the Mixed Lineage Kinase Domain-Like protein (MLKL) upon its phosphorylation.\"}, {\"id\": 2, \"text\": \"Under conditions of necroptotic cell death, ESCRT-III controls the duration of plasma membrane integrity.\"}, {\"id\": 5, \"text\": \"The activation of mixed lineage kinase-like (MLKL) by receptor-interacting protein kinase-3 (RIPK3) results in plasma membrane (PM) disruption and a form of\\u00c2\\u00a0regulated necrosis, called necroptosis.\"}, {\"id\": 18, \"text\": \"Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome\"}, {\"id\": 17, \"text\": \"Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\"}, {\"id\": 14, \"text\": \"chanisms by which the essential, and possibly terminal, necroptotic effector, MLKL, triggers the disruption of cellular membranes to cause cell lysis.\"}, {\"id\": 11, \"text\": \" Both necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise.\"}, {\"id\": 13, \"text\": \"Necroptosis is a form of regulated cell death which results in loss of plasma membrane integrity, release of intracellular contents, and an associated inflammatory response.\"}, {\"id\": 6, \"text\": \"Here we report that, following sciatic nerve injury, MLKL, a pseudokinase known to rupture cell membranes during necroptotic cell death, is induced and targets the myelin sheath membrane of Schwann cells to promote myelin breakdown.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [18, 17, 7, 4, 13, 9, 10, 5, 12, 16, 6, 2, 0, 11, 15, 14, 19, 1, 3, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the definition of dermatillomania?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. \"}, {\"id\": 1, \"text\": \"Dermatillomania is a pathologic grooming disorder characterized by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic condition.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What disease can be treated with Glofitamab?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab, anti-CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL. \"}, {\"id\": 0, \"text\": \"In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. \"}, {\"id\": 2, \"text\": \"Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma.\"}, {\"id\": 3, \"text\": \"Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.\"}, {\"id\": 1, \"text\": \"Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 0, 1, 4, 2]}"}]}
